[go: up one dir, main page]

US6573264B1 - Heteroaryl alkyl piperazine derivatives - Google Patents

Heteroaryl alkyl piperazine derivatives Download PDF

Info

Publication number
US6573264B1
US6573264B1 US09/694,155 US69415500A US6573264B1 US 6573264 B1 US6573264 B1 US 6573264B1 US 69415500 A US69415500 A US 69415500A US 6573264 B1 US6573264 B1 US 6573264B1
Authority
US
United States
Prior art keywords
group
hydrogen
compound
optionally substituted
straight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/694,155
Inventor
Jeff Zablocki
Prabha N. Ibrahim
Kevin Shenk
Elfatih Elzein
Venkata Palle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Assigned to CV THERAPEUTICS, INC. reassignment CV THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ELZEIN, ELFATIH O., PALLE, VENKATA P., SHENK, KEVIN, ZABLOCKI, JEFF A., IBRAHIM, PRABHA N.
Priority to US09/694,155 priority Critical patent/US6573264B1/en
Priority to RU2003115351/04A priority patent/RU2243970C1/en
Priority to JP2002564509A priority patent/JP4138489B2/en
Priority to PL36200401A priority patent/PL362004A1/en
Priority to US10/398,636 priority patent/US20040029889A1/en
Priority to PCT/US2001/051032 priority patent/WO2002064576A1/en
Priority to DE60126643T priority patent/DE60126643T2/en
Priority to NZ525259A priority patent/NZ525259A/en
Priority to MXPA03003531A priority patent/MXPA03003531A/en
Priority to HU0303552A priority patent/HUP0303552A3/en
Priority to IL15529401A priority patent/IL155294A0/en
Priority to CNB018177700A priority patent/CN1303074C/en
Priority to AU2002255466A priority patent/AU2002255466B2/en
Priority to KR10-2003-7005645A priority patent/KR20030044029A/en
Priority to CA002426535A priority patent/CA2426535A1/en
Priority to EP01271075A priority patent/EP1339701B1/en
Priority to AT01271075T priority patent/ATE353882T1/en
Priority to SI200130708T priority patent/SI1339701T1/en
Priority to PT01271075T priority patent/PT1339701E/en
Priority to ES01271075T priority patent/ES2279790T3/en
Priority to HK04101193.9A priority patent/HK1058364B/en
Priority to TW090126173A priority patent/TWI286135B/en
Priority to ARP010104957A priority patent/AR034173A1/en
Priority to US10/313,818 priority patent/US6849632B2/en
Priority to IL155294A priority patent/IL155294A/en
Priority to ZA200302990A priority patent/ZA200302990B/en
Priority to NO20031784A priority patent/NO20031784L/en
Priority to NO20031797A priority patent/NO325220B1/en
Publication of US6573264B1 publication Critical patent/US6573264B1/en
Application granted granted Critical
Priority to US10/813,743 priority patent/US20040192702A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Definitions

  • the present invention is concerned with piperazine derivatives, therapeutic dosage forms including one or more of the derivatives, and methods for treating diseases in mammals, and in particular, in a human in a therapy selected from the group including protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
  • a therapy selected from the group including protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart
  • U.S. Pat. No. 4,567,264 discloses a class of substituted piperazine compounds that includes a compound known as ranolazine, ( ⁇ )-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]-1-piperazineacetamide, and its pharmaceutically acceptable salts, and their use in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise-induced angina, and myocardial infarction.
  • ranolazine a compound known as ranolazine
  • ( ⁇ )-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]-1-piperazineacetamide and its pharmaceutically acceptable salts, and their use in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise-induced angina, and myocardial infarction.
  • U.S. Pat. No. 5,506,229 which is incorporated herein by reference, discloses the use of ranolazine and its pharmaceutically acceptable salts and esters for the treatment of tissues experiencing a physical or chemical insult, including cardioplegia, hypoxic or reperfusion injury to cardiac or skeletal muscle or brain tissue, and for use in transplants.
  • ranolazine is particularly useful for treating arrhythmias, variant and exercise-induced angina, and myocardial infarction by partially inhibiting cardiac fatty acid oxidation.
  • Conventional oral and parenteral ranolazine formulations are disclosed, including controlled release formulations.
  • Example 7D of U.S. Pat. No. 5,506,229 describes a controlled release formulation in capsule form comprising microspheres of ranolazine and microcrystalline cellulose coated with release controlling polymers.
  • ranolazine is a very useful cardiac therapeutic agent
  • This invention includes novel heteroaryl alkyl piperazine derivatives that are partial fatty acid oxidation inhibitors with good therapeutic half-lives.
  • This invention also includes novel substituted piperazine compounds that can be administered to a mammal to protect skeletal muscles against damage resulting from trauma, to protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
  • novel substituted piperazine compounds that can be administered to a mammal to protect skeletal muscles against damage resulting from trauma, to protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
  • This invention includes a class of substituted piperazine compounds having the formula:
  • R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 SO 2 R 22 , C 1-15 alkyl, C 2-15 alkenyl, C 2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent selected from the group consisting of halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , and SO 2 R 22 ;
  • R 6 , R 7 and R 8 each independently selected from the group consisting of hydrogen or C 1-3 alkyl
  • R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently selected from the group consisting of hydrogen, CO 2 R 20 , CON(R 20 ) 2 , C 1-4 alkyl, or aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF 3 , CN, OR 20 , N(R 20 ) 2 , CO 2 R 20 , CON(R 20 ) 2 or aryl, wherein R 9 and R 10 may together form a carbonyl, or R 11 and R 12 may together form a carbonyl, or R 13 and R 14 may together form a carbonyl, or R 15 and R 16 may together form a carbonyl or R 11 and R 13 or R 9 and R 15 or R 9 and R 11 may join together to form a ring including from 1 to 3 carbon atoms;
  • R 17 is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 SO 2 R 22 , C 1-15 alkyl, C 2-15 alkenyl, C 2-15 alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , or SO 2 R 22 ;
  • R 20 is selected from the group consisting of H, C 1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, mono- or dialkylamino, alkyl CN, —O—C 1-6 alkyl, or CF 3 ; and
  • R 22 is selected from the group consisting of C 1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O—C 1-6 alkyl, CF 3 , or heteroaryl.
  • this invention is a substituted piperazine compound selected from the group consisting of N-(2,6-dimethyl-phenyl)-2-(4- ⁇ 2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl ⁇ -piperazin-1-yl)acetamide, 2- ⁇ 4-[3-(benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl ⁇ -N-(2,6-dimethylphenyl)acetamide, N-(2,6-dimethylphenyl)-2- ⁇ 4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl ⁇ acetamide,4-(3- ⁇ 4-[(2,6-dimethylphenylcarbamoyl)-methyl]-piperazin-1-yl ⁇ -2-hydroxy-propoxy)-1H-indole-2-car
  • this invention is a method for administering one or more composition of this invention to a mammal in a treatment selected from the group consisting of protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
  • a treatment selected from the group consisting of protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
  • a class of substituted piperazine compounds having the following formula:
  • R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 SO 2 R 22 , C 1-15 alkyl, C 2-15 alkenyl, C 2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent selected from the group consisting of halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , and SO 2 R 22 ;
  • R 6 , R 7 and R 8 each independently selected from the group consisting of hydrogen or C 1-3 alkyl
  • R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently selected from the group consisting of hydrogen, CO 2 R 20 , CON(R 20 ) 2 , C 1-4 alkyl, or aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF 3 , CN, OR 20 , N(R 20 ) 2 , CO 2 R 20 , CON(R 20 ) 2 or aryl, wherein R 9 and R 10 may together form a carbonyl, or R 11 and R 12 may together form a carbonyl, or R 13 and R 14 may together form a carbonyl, or R 15 and R 16 may together form a carbonyl or R 11 and R 13 or R 9 and R 15 or R 9 and R 11 may join together to form a ring including from 1 to 3 carbon atoms;
  • R 17 is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 SO 2 R 22 , C 1-15 alkyl, C 2-15 alkenyl, C 2-15 alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , or SO 2 R 22 ;
  • R 20 is selected from the group consisting of H, C 1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, mono- or dialkylamino, alkyl, CN, —O—C 1-6 alkyl, or CF 3 ; and
  • R 22 is selected from the group consisting of C 1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O—C 1-6 alkyl, CF 3 , or heteroaryl.
  • q NH or O.
  • R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, halo, CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , SO 2 N(R 20 ) 2 , CO 2 R 20 , CON(R 20 ) 2 , C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , or SO 2 R 22 .
  • R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, halo, CF 3 , OR 20 , C 1-5 alkyl, C 2-5 alkenyl, or C 2-5 alkynyl, wherein the alkyl substituent is optionally substituted with CF 3 .
  • R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, halo, CF 3 , OR 20 , or C 1-3 alkyl wherein the alkyl substituent is optionally substituted with CF 3 .
  • R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, CF 3 , OR 20 , or C 1-2 alkyl, with hydrogen, OR 20 , or methyl being more preferred and hydrogen or methyl being most preferred.
  • R 6 , R 7 and R 8 each independently selected from the group consisting of hydrogen or C 1-3 alkyl and most preferably hydrogen or methyl.
  • R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently selected from the group consisting of hydrogen, CON(R 20 ) 2 , C 1-4 alkyl, or wherein R 9 and R 11 may together form a carbonyl, or R 11 and R 12 may together form a carbonyl, or R 13 and R 14 may together form a carbonyl, or R 15 and R 16 may together form a carbonyl.
  • R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently selected from the group consisting of hydrogen or C 1-2 alkyl, wherein R 9 and R 10 may together form a carbonyl, or R 11 and R 12 may together form a carbonyl, or R 13 and R 14 may together form a carbonyl, or R 15 and R 16 may together form a carbonyl.
  • R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently selected from the group consisting of hydrogen, or methyl, wherein R 9 and R 10 may together form a carbonyl, or R 11 and R 12 may together form a carbonyl, or R 13 and R 14 may together form a carbonyl, or R 15 and R 16 may together form a carbonyl.
  • R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently selected from the group consisting of hydrogen, or C 1-2 alkyl, wherein the alkyl substituent is optionally substituted with 1 substituent selected from the group consisting of N(R 20 ) 2 , or aryl or wherein R 9 and R 10 may together form a carbonyl.
  • R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently selected from the group consisting of hydrogen or C 1-2 alkyl, or wherein R 9 and R 10 may together form a carbonyl.
  • R 11 and R 15 are each selected from the group consisting of hydrogen or methyl
  • R 9 , R 11 , R 12 , R 13 , R 14 and R 16 are each hydrogen and R 9 and R 10 may together form a carbonyl.
  • R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each hydrogen.
  • R 17 is a heteroaryl that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF 3 , OR 20 , N(R 20 ) 2 , CON(R 20 ) 2 , C 1-3 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF 3 , OR 20 , or N(R 20 ) 2 .
  • R 17 is a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 5 heteroatoms each selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 SO 2 R 22 , C 1-15 alkyl, C 2-15 alkenyl, C 2-15 alkynyl, heteroaryl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO 2
  • R 17 is preferably a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 3 heteroatoms selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF 3 , OR 20 , N(R 20 ) 2 , CON(R 20 ) 2 , C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF 3 , OR 20 , or N(R 20 ) 2 .
  • R 17 is a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 2 heteroatoms selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF 3 , OR 20 , N(R 20 ) 2 , CON(R 20 ) 2 , C 1-3 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF 3 , or OR 20 .
  • R 17 is a heteroaryl that is a fused 6,5 membered ring system selected from the group consisting of indole, benzothiazole, and benzoxazole that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF 3 , OR 20 , N(R 20 ) 2 , CON(R 20 ) 2 , C 1-3 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF 3 , or OR 20 .
  • R 17 is preferably benzothiazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, halo, CF 3 , OR 20 , N(R 20 ) 2 , CON(R 20 ) 2 , C 1-3 alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF 3 . More preferably R 17 is benzothiazole that is optionally substituted at the 2-position with 1 substituent selected from the group consisting of hydrogen, methyl or phenyl.
  • R 17 is 5-substituted benzothiazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, halo, CF 3 , OR 20 , N(R 20 ) 2 , CON(R 20 ) 2 , C 1-3 alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF 3 .
  • the 5-substituted benzothiazole is preferably substituted at the 2-position with 1 substituent selected from the group consisting of hydrogen, methyl or phenyl.
  • R 17 is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 4 nitrogen atoms that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 SO 2 R 22 , C 1-15 alkyl, C 2-15 alkenyl, C 2-15 alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO 2 , CF 3 , CN, OR 20 , SR
  • R 17 is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 3 nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF 3 , OR 20 , N(R 20 ) 2 , CON(R 20 ) 2 , C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF 3 , OR 20 , or N(R 20 ) 2 .
  • R 17 is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 2 nitrogen atoms that is optionally substituted with methyl;
  • R 17 is a 5 or 6-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, S, or O that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 SO 2 R 22 , C 1-15 alkyl, C 2-15 alkenyl, C 2-15 alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO 2 , CF 3 ,
  • R 17 is a 5 or 6 membered ring including from 1 to 3 heteroatoms selected from N, S, or O nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF 3 , OR 20 , N(R 20 ) 2 , CON(R 20 ) 2 , C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF 3 , OR 20 , or N(R 20 ) 2 .
  • R 17 is a 6 membered ring including from 1 to 2 nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF 3 , OR 20 , N(R 20 ) 2 , CON(R 20 ) 2 , C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF 3 , OR 20 , or N(R 20 ) 2 .
  • R 17 is a 6 membered ring containing from 1 to 2 nitrogen atoms that is optionally substituted with methyl.
  • R 17 is a heteroaryl that is a fused 6,5 membered ring system selected from the group consisting of benzothiazole, and benzoxazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, CF 3 , OR 20 , C 1-3 alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF 3 and preferably optionally substituted with methyl.
  • R 20 is selected from the group consisting of H, C 1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkylcyano, —O—C 1-6 alkyl, or CF 3 .
  • R 20 is selected from the group consisting of H, C 1-5 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, —OMe, or CF 3 .
  • R 20 is selected from the group consisting of H, C 1-3 alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent individually selected from the group consisting of halo, —OMe, and CF 3 . Most preferably, R 20 is selected from the group consisting of H or C 1-3 alkyl and most preferably H or methyl.
  • R 22 is selected from the group consisting of C 1-15 alkyl, aryl, or heteroaryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O—C 1-6 alkyl, CF 3 , or heteroaryl.
  • this invention is a substituted piperazine compound selected from the group consisting of N-(2,6-dimethyl-phenyl)-2-(4- ⁇ 2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl ⁇ -piperazin-1-yl)acetamide, 2- ⁇ 4-[3-(benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl ⁇ -N-(2,6-dimethylphenyl)acetamide, N-(2,6-dimethylphenyl)-2- ⁇ 4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl ⁇ acetamide,4-(3- ⁇ 4-[(2,6-dimethylphenylcarbamoyl)-methyl]-piperazin-1-yl ⁇ -2-hydroxy-propoxy)-1 H-indole
  • Halo or “Halogen”—alone or in combination means all halogens, that is, chloro (Cl), fluoro (F), bromo (Br), iodo (I).
  • Haldroxyl refers to the group —OH.
  • Thiol or “mercapto” refers to the group —SH.
  • Alkyl alone or in combination means an alkane-derived radical containing from 1 to 20, preferably 1 to 15, carbon atoms (unless specifically defined). It is a straight chain alkyl, branched alkyl or cycloalkyl. Preferably, straight or branched alkyl groups containing from 1-15, more preferably 1 to 8, even more preferably 1-6, yet more preferably 1-4 and most preferably 1-2, carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl and the like.
  • the term “lower alkyl” is used herein to describe the straight chain alkyl groups described immediately above.
  • cycloalkyl groups are monocyclic, bicyclic or tricyclic ring systems of 3-8, more preferably 3-6, ring members per ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and the like.
  • Alkyl also includes a straight chain or branched alkyl group that contains or is interrupted by a cycloalkyl portion. The straight chain or branched alkyl group is attached at any available point to produce a stable compound. Examples of this include, but are not limited to, 4-(isopropyl)-cyclohexylethyl or 2-methyl-cyclopropylpentyl.
  • a substituted alkyl is a straight chain alkyl, branched alkyl, or cycloalkyl group defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbon
  • Alkenyl—alone or in combination means a straight, branched, or cyclic hydrocarbon containing 2-20, preferably 2-17, more preferably 2-10, even more preferably 2-8, most preferably 2 to 4 carbon atoms with at least one, preferably 1-3, more preferably 1-2, and most preferably one, carbon to carbon double bond.
  • a cycloalkyl group conjugation of more than one carbon to carbon double bond is not such as to confer aromaticity to the ring.
  • Carbon to carbon double bonds may be either contained within a cycloalkyl portion, with the exception of cyclopropyl, or within a straight chain or branched portion.
  • alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, cyclohexenyl, cyclohexenylalkyl and the like.
  • a substituted alkenyl is the straight chain alkenyl, branched alkenyl or cycloalkenyl group defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups,
  • Alkynyl alone or in combination means a straight or branched hydrocarbon containing 2-20, preferably 2-17, more preferably 2-10, even more preferably 2-8, most preferably 2-4, carbon atoms containing at least one, preferably one, carbon to carbon triple bond.
  • alkynyl groups include ethynyl, propynyl, butynyl and the like.
  • a substituted alkynyl refers to the straight chain alkynyl or branched alkynyl defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonyla
  • Alkyl alkynyl refers to a groups —RC ⁇ CR′ where R is lower alkyl or substituted lower alkyl, R′ is hydrogen, lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined below.
  • Alkoxy denotes the group —OR, where R is lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroalkyl, heteroarylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, or substituted cycloheteroalkyl as defined.
  • Acyl denotes groups —C(O)R, where R is hydrogen, lower alkyl substituted lower alkyl, aryl, substituted aryl and the like as defined herein.
  • Aryloxy denotes groups —OAr, where Ar is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl group as defined herein.
  • Amino denotes the group NRR′, where R and R′ may independently by hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined herein or acyl.
  • “Amido” denotes the group —C(O)NRR′, where R and R′ may independently by hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, substituted hetaryl as defined herein.
  • Carboxyl denotes the group —C(O)OR, where R is hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, and substituted hetaryl as defined herein.
  • Aryl alone or in combination means phenyl or naphthyl optionally carbocyclic fused with a cycloalkyl of preferably 5-7, more preferably 5-6, ring members and/or optionally substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino
  • Substituted aryl refers to aryl optionally substituted with one or more functional groups, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • functional groups e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Heterocycle refers to a saturated, unsaturated, or aromatic carbocyclic group having a single ring (e.g., morpholino, pyridyl or furyl) or multiple condensed rings (e.g., naphthpyridyl, quinoxalyl, quinolinyl, indolizinyl or benzo[b]thienyl) and having at least one hetero atom, such as N, O or S, within the ring, which can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • a single ring e.g., morpholino, pyridy
  • Heteroaryl alone or in combination means a monocyclic aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing one or more, preferably 1-4, more preferably 1-3, even more preferably 1-2, heteroatoms independently selected from the group O, S, and N, and optionally substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkyl
  • Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen.
  • a carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable aromatic ring is retained.
  • heteroaryl groups are pyridinyl, pyridazinyl, pyrazinyl, quinazolinyl, purinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrrolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazinyl, furanyl, benzofuryl, indolyl, benzothiazolyl, benzoxazolyl, and the like.
  • a substituted heteroaryl contains a substituent attached at an available carbon or nitrogen to produce a stable compound.
  • Heterocyclyl alone or in combination means a non-aromatic cycloalkyl group having from 5 to 10 atoms in which from 1 to 3 carbon atoms in the ring are replaced by heteroatoms of O, S or N, and are optionally benzo fused or fused heteroaryl of 5-6 ring members and/or are optionally substituted as in the case of cycloalkyl.
  • Heterocycyl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. The point of attachment is at a carbon or nitrogen atom.
  • heterocyclyl groups are tetrahydrofuranyl, dihydropyridinyl, piperidinyl, pyrrolidinyl, piperazinyl, dihydrobenzofuryl, dihydroindolyl, and the like.
  • a substituted hetercyclyl contains a substituent nitrogen attached at an available carbon or nitrogen to produce a stable compound.
  • Substituted heteroaryl refers to a heterocycle optionally mono or poly substituted with one or more functional groups, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • functional groups e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Alkyl refers to the group —R—Ar where Ar is an aryl group and R is lower alkyl or substituted lower alkyl group.
  • Aryl groups can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Heteroalkyl refers to the group —R-Het where Het is a heterocycle group and R is a lower alkyl group. Heteroalkyl groups can optionally be unsubstituted or substituted with e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Heteroarylalkyl refers to the group —R-HetAr where HetAr is an heteroaryl group and R lower alkyl or substituted lower alkyl.
  • Heteroarylalkyl groups can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, substituted lower alkyl, alkoxy, alkylthio, acetylene, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl,.nitro, cyano, thiol, sulfamido and the like.
  • Cycloalkyl refers to a divalent cyclic or polycyclic alkyl group containing 3 to 15 carbon atoms.
  • “Substituted cycloalkyl” refers to a cycloalkyl group comprising one or more substituents with, e.g., halogen, lower alkyl, substituted lower alkyl, alkoxy, alkylthio, acetylene, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Cycloheteroalkyl refers to a cycloalkyl group wherein one or more of the ring carbon atoms is replaced with a heteroatom (e.g., N, O, S or P).
  • “Substituted cycloheteroalkyl” refers to a cycloheteroalkyl group as herein defined which contains one or more substituents, such as halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • substituents such as halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Alkyl cycloalkyl denotes the group —R-cycloalkyl where cycloalkyl is a cycloalkyl group and R is a lower alkyl or substituted lower alkyl.
  • Cycloalkyl groups can optionally be unsubstituted or substituted with e.g. halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Alkyl cycloheteroalkyl denotes the group —R-cycloheteroalkyl where R is a lower alkyl or substituted lower alkyl.
  • Cycloheteroalkyl groups can optionally be unsubstituted or substituted with e.g. halogen, lower alkyl, lower alkoxy, alkylthio, amino, amido, carboxyl, acetylene, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • “Optional” and “optionally” mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
  • “optional pharmaceutical excipients” indicates that a formulation so described may or may not include pharmaceutical excipients other than those specifically stated to be present, and that the formulation so described includes instances in which the optional excipients are present and instances in which they are not.
  • Treating” and “treatment” refer to any treatment of a disease in a mammal, particularly a human, and include:
  • All of the aforementioned embodiments include the pharmaceutically acceptable acid addition salts thereof, particularly the mono- and dihydrochlorides, and mixtures thereof.
  • a general synthesis of the compounds of this invention is outlined in Scheme 1.
  • Compound IV can be prepared by N-acylation of substituted aniline II with 2-substituted chloroacetylchloride III.
  • Compound II is available commercially or readily prepared through reduction of the corresponding nitrobenzene derivative (acid/SnCl 2 or catalytic hydrogenation, see Advanced Organic Chemistry, Ed. J. March, (1992) A. Wiley-Interscience).
  • Some examples of commercially available substituted anilines corresponding to general structure II include 2,6-dimethylaniline, 2,3-dimethylaniline, 2-methylaniline, 4-methylaniline, 4-methylaniline, 2,4-dichloroaniline, 3,4-dichloroaniline, 2,5-dichloroaniline, 2,4-dichloroaniline, 2-chloroaniline, 3-chloroaniline, 2,6-difluoroaniline, 2,5-difluoroaniline, 3,4-difluoroaniline, 2-fluoroaniline, 4-fluoroaniline, 3-fluoroaniline, 2-fluoro-6-chloroaniline, 4-fluoro-3-chloroaniline, 4-acetoxyaniline.
  • Compound VI can be obtained by reacting compound IV with N-protected substituted piperazine V through warming in an appropriate solvent (e.g. DMF, EtOH). Protection of the nitrogen of compound V is only required when it is useful to control the regiochemistry of the addition of Compound V with compound IV. In some cases, compound V can be obtained from commercial resources.
  • an appropriate solvent e.g. DMF, EtOH.
  • Examples of commercially available compounds corresponding to general structure V include 2-methylpiperazine, 2,5-dimethylpiprazine, 2,6-dimethylpiperazine, 2,3,5,6-tetramethylpiperazine, piperazine-2-carboxylic acid, perhydroquinoxaline, 2-aminomethyl-6-methylpiperazine, 2-aminomethylpiperazine, 2-(o-chlorophenyl)piperazine, and 2-(m-chlorophenyl)piperazine.
  • Deprotection of compound VI can be accomplished using the standard conditions (e.g. for Boc group use TFA, for CBZ and benzyl use hydrogenation).
  • Compound Ia or Ic can be prepared by reacting compound VII with epoxide VIII through warming in an appropriate solvent (ethanol, DMF, CHCl 2 , THF) or by stirring at room temperature in the presence of a lanthamide (III) Lewis acid (Chini, M et al., Tetrahedron Lett ., 35: 433-36 (1994).
  • Compound IX can be obtained from commercial resources. Examples of commercially available compounds corresponding to structure XI include 2-methyl-5-hydroxybenzothiazole, 2-hydroxybenzothiazole, 8-hydroxyquinolidine, 6-hydroxyquinoline, 4-hydroxyquinoline, 5-hydroxyisoquinoline, 3-hydroxypyridine, 2-quinoxalinol, and 4-(imidazol-1-yl)phenol. In some cases compound VIII can be obtained from commercial sources. Examples of commercially available compounds corresponding to general structure VIII include 4-glycidyloxy-2-indolecarboxamide.
  • Compound IX can in turn be prepared by the deprotection of the corresponding methyl or benzyl ethers (X) using Lewis acids as shown in Scheme 3 (BBr 3 , BF 3 , etc.—see Advanced Organic Chemistry, Ed. J. March (1992) A. Wiley Intersciences, p 434).
  • Benzyl ethers can also be deprotected by refluxing with palladium hydroxide in ethanol/cyclohexene (see Catalytic hydrogenation over platinum metals, P. N. Rylander, Academic Press, New York, N.Y., (1976) p 464).
  • Commercially available methyl ethers include 6-methoxy-2-methyl-benzothiazole.
  • Compound IX can also be prepared by the diazotization of the corresponding amino compounds (XI) as shown in Scheme 4 (Boggust, W. A and Cocker, W. J. Chem. Soc. 1949, 355).
  • Commercially available amines include 6-amino-benzothiazole.
  • the 6, 5 fused ring system of compound X can be prepared by the cyclization of commercially available ethers of 2-aminophenols, 2-aminothiophenols, or 2-aminoanilines (XII) with orthoesters (XIII) (Musser, J. H. et al., J. Med. Chem. 1985, 28, 1255-1259) or imidates (XIV) (Gregory, G. I. Et al., J. Chem. Soc. Perkin Trans. 1, 1973, 47-51) as shown in Scheme 5 and 6 respectively.
  • ethers of aminophenols include 4-methoxy-2-aminophenol
  • orthoesters include trimethyl orthoformate and trimethyl orthoacetate
  • imidates include ethyl acetimidate hydrochloride, and ethyl benzimidate hydrochloride.
  • the thiophenol analog of compound XII can be prepared from the commercially available compound XV by reacting with sodium disulfide hydrate followed by reduction using tin and hydrochloric acid ( Dannley, R. L. and Zazaris, D. A; Can. J. Chem. 1965, 43, 2610-2612) as shown in Scheme 7.
  • Commercially available nitro compounds include 3-nitro-4-chloroanisole.
  • Imidate XIV can be prepared by bubbling HCI gas through an alcoholic solution of the commercially available nitrites XVI as shown in Scheme 8.
  • Commercially available nitriles include, benzonitrile, 4-trifluoromethylbenzonitrile and 3-trifluoromethylbenzonitrile.
  • Sulfur containing 6,5 fused ring system of compound X can also be prepared from the commercially available ethers of anilines XVII (Stevens, M. F. G. et al, J. Med. Chem. 1994, 37, 1689-1695) as shown in Scheme 9.
  • Thioamide XX can be obtained by the reaction of Lawesson's reagent with amide XIX which in turn can be prepared by the reaction of compound XVII with compound XVIII. Cyclization of XX with potassium ferrocyanide under basic conditions can afford compound XXI.
  • Commercially available ethers of anilines include benzyloxyanilines and anisidines.
  • a general synthesis of the compound XXV of this invention is outlined in Scheme 10.
  • Compound XXIV can be prepared by the deprotection of compound XXIII using the standard conditions (e.g. for BOC group use TFA, for CBZ and benzyl use hydrogenation).
  • Compound XXIII in turn can be prepared by the reaction of the commercially available protected monoketopiperazine analog compound XXII with compound IV and sodium hydride in an appropriate solvent (DMF, THF).
  • An example of the commercially available monoketopiperazines include 4-benzyloxycarbonylpiperazine-2-one.
  • Compound XXVII can be prepared by refluxing compound VII with the epoxide XXVI in a suitable solvent (ethanol, THF). Deprotection of compound XXVII can be accomplished by using standard conditions (e.g. for BOC group use TFA; for CBZ use hydrogenation or Pd(OH) 2 ). Compound Ib can be prepared by refluxing compound XXVIII with compound XXIX in a suitable solvent (ethanol, THF).
  • compound XXIX includes 2-chlorobenzothiazole, 2-chlorobenzoxazole, 2-chloropyridine, 2-chloropyrimidine, 2-chloro-4-(trifluoromethyl)pyrimidine, and chloropyrazine.
  • Epoxide XXVI in turn can be prepared as shown in Scheme 12.
  • Commercially available compound XXX can be protected using the standard conditions (for BOC protection use BOC anliydride; for CBZ protection use CBZ-Cl).
  • Compound XXV can be prepared by the reaction of compound XXXI using m-chloroperbenzoic acid in a suitable solvent (e.g. dichloromethane).
  • a suitable solvent e.g. dichloromethane
  • An example of a commercially available compound XXX includes by is not limited to allylamine.
  • Compound V can be prepared as described in Scheme 13. Alkylation of compound XXXII with alkyl halides using t-BuLi as base can afford compound XXXIII as described by Pohlman et. al. (J. Org. Chem, 1997, 62, 1016-1022). Reduction of XXXIV using diborane can afford the N-benzyl protected version of compound V after N-Boc deprotection with trifluoroacetic acid (TFA) [for the diborane reduction see Jacobson et. al, J. Med. Chem, 1999, 42, 1123-1144].
  • TFA trifluoroacetic acid
  • Compound V can also be prepared through standard coupling (eg. EDC or PyBroP) of D or L amino acids and standard deprotection as outlined in Scheme 14 (Cledera, P. et al. Tetrahedron, 1998 p. 12349-12360; Smith, R. A. et al Bioorg. Med. Chem. Lett. 1998, p. 2369-2374). Reduction of the diketopiperazine XXXVII with diborane can afford the N-benzyl protected version of compound V.
  • Compound V can also be prepared as described in Scheme 15. Bromination of aldehydes XXXVIII followed by the reaction with ethylene diamine can afford the imine XLI. Catalytic hydrogenation of compound XLI can afford compound V (Bogeso, K. P., et al, J. Med. Chem. 1995, 38, p 4380-4392).
  • Commercially available aldehydes include isobutyraldehyde.
  • Compound V also includes the bicyclic homologs of piperazine (1S,4S)-(+)-2,5-diazabicyclo[2.2.1]heptane 83, 3,8-diazabicyclo[3.2.1] octane 84, and 2,5-diazabicyclo[2.2.2] octane 85.
  • bicyclic analogs include (1S,4S)-(+)-2,5-diazabicyclo[2.2.1]heptane 83.
  • Compounds 84, 85, and the (1R,4R) isomer of 83 can be prepared by published procedures (for 84 and 85- see Sturm, P. A. et al, J. Med. Chem. 1974, 17, 481-487; for 83 see—Barish, T. F. and Fox, D. E. J. Org. Chem., 1990, 55, 1684-1687).
  • the benzoxazole derivative 8 was prepared by the deprotection of compound 13 as shown in Scheme 18.
  • Compound 10 was prepared by condensation of 2-amino-4-methoxyphenol 12.
  • Compound 12 was obtained by the catalytic hydrogenation of the commercially available 4-methoxy-2-nitrophenol 11, and the benzimidate derivative 13 as shown in Scheme 19.
  • Compound 13 was obtained from 3-trifluoromethylbenzonitrile 14 using a Pinner reaction (ethanoluanhydrous HCl).
  • Compound 22 can be prepared by the reduction of compound 21 with tin and hydrochloric acid as shown in Scheme 23.
  • Compound 21 was synthesized by reacting compound 20 with sodium disulfide hydrate.
  • Compound 26 was prepared by the reaction of compound 25 with Lawesson's reagent as shown in Scheme 24.
  • Compound 25 was prepared by the reaction of the aniline 23 with benzoyl chloride 24. Cyclization of the thioamide 26 with potassium ferrocyanide in aqueous sodium hydroxide gave a mixture of compounds 27 and 28. Compounds 27 and 28 were separated by column chromatography.
  • Epoxide 35 was synthesized as described in Scheme 28. Allylamine 40 was reacted with benzyl chloroformate in dichloromethane to afford compound 42. Reaction of m-chloroperbenzoic acid with 42 gave the epoxide 35.
  • the acid addition salts of the compounds of this invention may be converted to the corresponding free base by treating with a suitable base, such as potassium carbonate or sodium hydroxide, typically in the presence of aqueous solvent, and at a temperature of between about 0 degrees C. and 100 degrees C.
  • a suitable base such as potassium carbonate or sodium hydroxide
  • the free base form is isolated by conventional means, such as extraction with an organic solvent.
  • Salts of the compounds of this invention may be interchanged by taking advantage of differential solubilities and volatilities, or by treating with the appropriately loaded ion exchange resin. This conversion is carried out at a temperature between about 0° C. and the boiling point of the solvent being used as the medium for the procedure.
  • Administration of the active compounds and salts described herein can be via any of the accepted modes of administration for therapeutic agents. These methods include oral, parenteral, transdermal, subcutaneous and other systemic modes. The preferred method of administration is oral, except in those cases where the subject is unable to ingest, by himself, any medication. In those instances it may be necessary to administer the composition parentarally.
  • compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages.
  • the compositions may include one or more conventional pharmaceutical excipients and at least one active compound of this invention or the pharmaceutically acceptable salts thereof and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.
  • the amount of active compound administered will, of course, be dependent on the subject being treated, the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. However, an effective dosage is in the range of 0.1-30 mg/kg/day, preferably 0.5-20 mg/kg/day. For an average 70 kg human, this would amount to 7-2100 mg per day, or preferably 35-1400 mg/day.
  • conventional non-toxic solid include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like may be used.
  • the active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, for example, propylene glycol, as the carrier.
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc.
  • an active compound as defined above and optional pharmaceutical adjuvants in a excipient such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • a excipient such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like.
  • the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • wetting or emulsifying agents such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • compositions or formulation to be administered will, in any event, contain a quantity of the active compound(s), a therapeutically effective amount, i.e. in an amount effective to alleviate the symptoms of the subject being treated.
  • a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like.
  • Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like.
  • Such compositions may contain 10%-95% active ingredient, preferably 1-70%.
  • Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
  • Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like.
  • the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
  • compositions of this invention can be administered orally in a sustained release dosage form using the compositions and/or methods disclosed in U.S. patent application Ser. No. 09/321,522, filed on May 27, 1999, the specification of which is incorporated herein by reference.
  • Compound 48 was prepared in the manner of compound 6 substituting compound 16 for compound 8 in partC-5 of Example 1.
  • Compound 50 was prepared from the commercially available 6-methoxy-2-methyl-benzothiazole as described in partC-4 of Example 1.
  • Compound 51 was prepared in the manner of compound 6 substituting compound 50 for compound 8 in partC-5 of Example 1.
  • Compound 53 was prepared in the manner of compound 3 substituting 2,6-dimethylpiperazine for piperazine in part A of Example 1.
  • Compound 56 was prepared in the manner of compound 3 substituting compound 55 for compound 1 in part A of Example 1.
  • Rat heart mitochondria were isolated by the method of Nedergard and Cannon (Methods in Enzymol. 55, 3, 1979).
  • Palmitoyl CoA oxidation The Palmityl CoA oxidation was carried out in a total volume of 100 micro liters containing the following agents: 110 mM KCl, 33 mM Tris buffer at pH 8, 2 mM KPi, 2 mM MgCl 2 , 0.1 mM EDTA, 14.7 microM defatted BSA, 0.5 mM malic acid, 13 mM carnitine, 1 mM ADP, 52 micrograms of mitochondrial protein, and 16 microM 1-C14 palmitoyl CoA (Sp. Activity 60 mCi/mmole; 20 microCi/ml, using 5 microliters per assay).
  • the compounds of this invention were added in a DMSO solution at the following concentrations: 100 microM, and 50 microM.
  • a DMSO control was used. After 15 min at 30° C., the enzymatic reaction was centrifuged (20,000 g for 1 min), and 70 microliters of the supernatant was added to an activated reverse phase silicic acid column (approximately 0.5 ml of silicic acid). The column was eluted with 2 ml of water, and 0.5 ml of the eluent was used for scintillation counting to determine the amount of C 14 trapped as C 14 bicarbonate ion.
  • Metabolic Stability As a measure of metabolic stability the compounds of this invention were incubated with human liver S-9 microsomal fractions. After, 30 minutes at 37 C, the amount of parent drug remaining was determined using LC-mass spec. The response factors for each compound was determined by establishing a standard curve and using an internal standard during the analysis of the samples. An average of five experiments for percentage of ranolazine remaining at the 30 minute time point is 57%. The compounds of this invention were assayed as described in the protocol below and the percentage of parent remaining was divided by the average % of ranolazine remaining (57%) affording a metabolic stability factor. A compound with a stability number greater than 1.2 has a better stability than ranolazine in the liver S-9 assay. A compound with a stability number between 1.2 and 0.8 has an equivalent stability in the liver S-9 assay. A compound with a stability number less than 0.8 is less stable than ranolazine in the liver S-9 assay.
  • the purpose of this experiment is to compare the percentages remaining for compounds of this invention with the percentage remaining for ranolazine after 30 minutes of incubation with human liver S9 fractions.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

Novel compounds of the general formula:
Figure US06573264-20030603-C00001
and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is concerned with piperazine derivatives, therapeutic dosage forms including one or more of the derivatives, and methods for treating diseases in mammals, and in particular, in a human in a therapy selected from the group including protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
2. Description of the Art
U.S. Pat. No. 4,567,264, the specification of which is incorporated herein by reference, discloses a class of substituted piperazine compounds that includes a compound known as ranolazine, (±)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]-1-piperazineacetamide, and its pharmaceutically acceptable salts, and their use in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise-induced angina, and myocardial infarction.
U.S. Pat. No. 5,506,229, which is incorporated herein by reference, discloses the use of ranolazine and its pharmaceutically acceptable salts and esters for the treatment of tissues experiencing a physical or chemical insult, including cardioplegia, hypoxic or reperfusion injury to cardiac or skeletal muscle or brain tissue, and for use in transplants. In particular, ranolazine is particularly useful for treating arrhythmias, variant and exercise-induced angina, and myocardial infarction by partially inhibiting cardiac fatty acid oxidation. Conventional oral and parenteral ranolazine formulations are disclosed, including controlled release formulations. In particular, Example 7D of U.S. Pat. No. 5,506,229 describes a controlled release formulation in capsule form comprising microspheres of ranolazine and microcrystalline cellulose coated with release controlling polymers.
Despite the important discovery that ranolazine is a very useful cardiac therapeutic agent, there remains a need for compounds that are partial fatty acid oxidation inhibitors that have a half-life greater than ranolazine and that have activities as least similar to ranolazine.
SUMMARY OF THE INVENTION
This invention includes novel heteroaryl alkyl piperazine derivatives that are partial fatty acid oxidation inhibitors with good therapeutic half-lives.
This invention also includes novel substituted piperazine compounds that can be administered to a mammal to protect skeletal muscles against damage resulting from trauma, to protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
This invention includes a class of substituted piperazine compounds having the formula:
Figure US06573264-20030603-C00002
wherein m=1, 2, or 3;
q=NH, O, or S;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, NR20CON(R20)2, COR20, CO2R20, CON(R20)2, NR20SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, and SO2R22;
R6, R7 and R8 each independently selected from the group consisting of hydrogen or C1-3 alkyl;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen, CO2R20, CON(R20)2, C1-4 alkyl, or aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF3, CN, OR20, N(R20)2, CO2R20, CON(R20)2 or aryl, wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl or R11 and R13 or R9 and R15 or R9 and R11 or R11 and R15 or R9 and R13 may join together to form a ring including from 1 to 3 carbon atoms;
R17 is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, NR20CON(R20)2, COR20, CO2R20, CON(R20)2, NR20SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, or SO2R22;
R20 is selected from the group consisting of H, C1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, mono- or dialkylamino, alkyl CN, —O—C1-6 alkyl, or CF3; and
R22 is selected from the group consisting of C1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O—C1-6 alkyl, CF3, or heteroaryl.
In another embodiment, this invention is a substituted piperazine compound selected from the group consisting of N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide, 2-{4-[3-(benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethylphenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide,4-(3-{4-[(2,6-dimethylphenylcarbamoyl)-methyl]-piperazin-1-yl}-2-hydroxy-propoxy)-1H-indole-2-carboxylic acid amide, 2-{4-[3-(benzothiazol-6-yloxy)2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethyl-phenyl)-acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-6-yloxy)-propyl]-piperazin-1-yl}aceamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-3,5-dimethyl-piperazine-1-yl}acetamide, 2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-N-(4-hydroxy-phenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-7-yloxy)-propyl]-piperazin-1-ylacetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-2-oxo-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(4-trifluoromethyl-phenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinoxalin-2-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(pyridin-3-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-4-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-quinolin-7-yloxy)-propyl]-piperazin-1-yl}acetamide, 2-{4-[3-(benzothiazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-(4-[3-(benzoxazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide and mixtures thereof.
In yet another embodiment, this invention is a method for administering one or more composition of this invention to a mammal in a treatment selected from the group consisting of protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
DETAILED DESCRIPTION OF THE INVENTION
A class of substituted piperazine compounds having the following formula:
Figure US06573264-20030603-C00003
wherein m=1, 2, or 3;
q=NH, O, or S;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, NR20CON(R20)2, COR20, CO2R20, CON(R20)2, NR20SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, and SO2R22;
R6, R7 and R8 each independently selected from the group consisting of hydrogen or C1-3 alkyl;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen, CO2R20, CON(R20)2, C1-4 alkyl, or aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF3, CN, OR20, N(R20)2, CO2R20, CON(R20)2 or aryl, wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl or R11 and R13 or R9 and R15 or R9 and R11 or R11 and R15 or R9 and R13 may join together to form a ring including from 1 to 3 carbon atoms;
R17 is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, NR20CON(R20)2, COR20, CO2R20, CON(R20)2, NR20SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, or SO2R22;
R20 is selected from the group consisting of H, C1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, mono- or dialkylamino, alkyl, CN, —O—C1-6 alkyl, or CF3; and
R22 is selected from the group consisting of C1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O—C1-6 alkyl, CF3, or heteroaryl.
In a preferred embodiment, q=NH or O.
In a preferred embodiment, R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, halo, CF3, CN, OR20, SR20, N(R20)2, SO2N(R20)2, CO2R20, CON(R20)2, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, or SO2R22. In another preferred embodiment, R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, halo, CF3, OR20, C1-5 alkyl, C2-5 alkenyl, or C2-5 alkynyl, wherein the alkyl substituent is optionally substituted with CF3. In yet another preferred embodiment, R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, halo, CF3, OR20, or C1-3 alkyl wherein the alkyl substituent is optionally substituted with CF3. More preferably R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, CF3, OR20, or C1-2 alkyl, with hydrogen, OR20, or methyl being more preferred and hydrogen or methyl being most preferred.
In a preferred embodiment, R6, R7 and R8 each independently selected from the group consisting of hydrogen or C1-3 alkyl and most preferably hydrogen or methyl.
In a preferred embodiment, R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen, CON(R20)2, C1-4 alkyl, or wherein R9 and R11 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl. In yet another embodiment, R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen or C1-2 alkyl, wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl. In a more preferred embodiment, R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen, or methyl, wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl. In another embodiment, R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen, or C1-2 alkyl, wherein the alkyl substituent is optionally substituted with 1 substituent selected from the group consisting of N(R20)2, or aryl or wherein R9 and R10 may together form a carbonyl. In another preferred embodiment, R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen or C1-2 alkyl, or wherein R9 and R10 may together form a carbonyl. In still another preferred embodiment, R11 and R15 are each selected from the group consisting of hydrogen or methyl, R9, R11, R12, R13, R14 and R16 are each hydrogen and R9 and R10 may together form a carbonyl. In another preferred embodiment, R9, R10, R11, R12, R13, R14, R15 and R16 are each hydrogen.
In one preferred embodiment, R17 is a heteroaryl that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF3, OR20, N(R20)2, CON(R20)2, C1-3 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF3, OR20, or N(R20)2. In another embodiment, R17 is a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 5 heteroatoms each selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, NR20CON(R20)2, COR20, CO2R20, CON(R20)2, NR20SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heteroaryl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, or SO2R22. In this embodiment, R17 is preferably a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 3 heteroatoms selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF3, OR20, N(R20)2, CON(R20)2, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF3, OR20, or N(R20)2. More preferably R17 is a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 2 heteroatoms selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF3, OR20, N(R20)2, CON(R20)2, C1-3 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF3, or OR20. Even more preferably in this embodiment, R17 is a heteroaryl that is a fused 6,5 membered ring system selected from the group consisting of indole, benzothiazole, and benzoxazole that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF3, OR20, N(R20)2, CON(R20)2, C1-3 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF3, or OR20. In this preferred embodiment, R17 is preferably benzothiazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, halo, CF3, OR20, N(R20)2, CON(R20)2, C1-3 alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF3. More preferably R17 is benzothiazole that is optionally substituted at the 2-position with 1 substituent selected from the group consisting of hydrogen, methyl or phenyl. In an alternative preferred embodiment, R17 is 5-substituted benzothiazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, halo, CF3, OR20, N(R20)2, CON(R20)2, C1-3 alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF3. The 5-substituted benzothiazole is preferably substituted at the 2-position with 1 substituent selected from the group consisting of hydrogen, methyl or phenyl.
In another preferred embodiment, R17 is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 4 nitrogen atoms that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, NR20CON(R20)2, COR20, CO2R20, CON(R20)2, NR20SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, or SO2R22. More preferably, R17 is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 3 nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF3, OR20, N(R20)2, CON(R20)2, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF3, OR20, or N(R20)2. Most preferably, R17 is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 2 nitrogen atoms that is optionally substituted with methyl;
In yet another preferred embodiment, R17 is a 5 or 6-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, S, or O that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, NR20CON(R20)2, COR20, CO2R20, CON(R20)2, NR20SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, or SO2R22. More preferably, R17 is a 5 or 6 membered ring including from 1 to 3 heteroatoms selected from N, S, or O nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF3, OR20, N(R20)2, CON(R20)2, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF3, OR20, or N(R20)2. Even more preferably, R17 is a 6 membered ring including from 1 to 2 nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF3, OR20, N(R20)2, CON(R20)2, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF3, OR20, or N(R20)2. Most preferably in this embodiment, R17 is a 6 membered ring containing from 1 to 2 nitrogen atoms that is optionally substituted with methyl.
In yet still another preferred embodiment, R17 is a heteroaryl that is a fused 6,5 membered ring system selected from the group consisting of benzothiazole, and benzoxazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, CF3, OR20, C1-3 alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF3 and preferably optionally substituted with methyl.
In a preferred embodiment, R20 is selected from the group consisting of H, C1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkylcyano, —O—C1-6 alkyl, or CF3. R20 is selected from the group consisting of H, C1-5 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, —OMe, or CF3. In a more preferred embodiment, R20 is selected from the group consisting of H, C1-3 alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent individually selected from the group consisting of halo, —OMe, and CF3. Most preferably, R20 is selected from the group consisting of H or C1-3 alkyl and most preferably H or methyl.
In a preferred embodiment, R22 is selected from the group consisting of C1-15 alkyl, aryl, or heteroaryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O—C1-6 alkyl, CF3, or heteroaryl.
In a most preferred embodiment, this invention is a substituted piperazine compound selected from the group consisting of N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide, 2-{4-[3-(benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethylphenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide,4-(3-{4-[(2,6-dimethylphenylcarbamoyl)-methyl]-piperazin-1-yl}-2-hydroxy-propoxy)-1 H-indole-2-carboxylic acid amide, 2-{4-[3-(benzothiazol-6-yloxy)2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethyl-phenyl)-acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-6-yloxy)-propyl]-piperazin-1-yl}aceamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-3,5-dimethyl-piperazine-1-yl}acetamide, 2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-N-(4-hydroxy-phenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6)-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-7-yloxy)-propyl]-piperazin-1-ylacetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-2-oxo-piperazin-1-yl}acetamide, N-(2,6)-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(4-trifluoromethyl-phenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide, N-(2,6-dimethylphenyl)-2-(4-[2-hydroxy-3-(quinoxalin-2-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6)-dimethylphenyl)-2-{4-[2-hydroxy-3-(pyridin-3-yloxy)-propyl]-piperazin-1)-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-4-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-quinolin-7-yloxy)-propyl]-piperazin-1-yl}acetamide, 2-{4-[3-(benzothiazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[3-(benzoxazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide and mixtures thereof.
The following definitions apply to terms as used herein.
“Halo” or “Halogen”—alone or in combination means all halogens, that is, chloro (Cl), fluoro (F), bromo (Br), iodo (I).
“Hydroxyl” refers to the group —OH.
“Thiol” or “mercapto” refers to the group —SH.
“Alkyl”—alone or in combination means an alkane-derived radical containing from 1 to 20, preferably 1 to 15, carbon atoms (unless specifically defined). It is a straight chain alkyl, branched alkyl or cycloalkyl. Preferably, straight or branched alkyl groups containing from 1-15, more preferably 1 to 8, even more preferably 1-6, yet more preferably 1-4 and most preferably 1-2, carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl and the like. The term “lower alkyl” is used herein to describe the straight chain alkyl groups described immediately above. Preferably, cycloalkyl groups are monocyclic, bicyclic or tricyclic ring systems of 3-8, more preferably 3-6, ring members per ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and the like. Alkyl also includes a straight chain or branched alkyl group that contains or is interrupted by a cycloalkyl portion. The straight chain or branched alkyl group is attached at any available point to produce a stable compound. Examples of this include, but are not limited to, 4-(isopropyl)-cyclohexylethyl or 2-methyl-cyclopropylpentyl. A substituted alkyl is a straight chain alkyl, branched alkyl, or cycloalkyl group defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like.
“Alkenyl”—alone or in combination means a straight, branched, or cyclic hydrocarbon containing 2-20, preferably 2-17, more preferably 2-10, even more preferably 2-8, most preferably 2 to 4 carbon atoms with at least one, preferably 1-3, more preferably 1-2, and most preferably one, carbon to carbon double bond. In the case of a cycloalkyl group, conjugation of more than one carbon to carbon double bond is not such as to confer aromaticity to the ring. Carbon to carbon double bonds may be either contained within a cycloalkyl portion, with the exception of cyclopropyl, or within a straight chain or branched portion. Examples of alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, cyclohexenyl, cyclohexenylalkyl and the like. A substituted alkenyl is the straight chain alkenyl, branched alkenyl or cycloalkenyl group defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, carboxy, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, or the like attached at any available point to produce a stable compound.
“Alkynyl”—alone or in combination means a straight or branched hydrocarbon containing 2-20, preferably 2-17, more preferably 2-10, even more preferably 2-8, most preferably 2-4, carbon atoms containing at least one, preferably one, carbon to carbon triple bond. Examples of alkynyl groups include ethynyl, propynyl, butynyl and the like. A substituted alkynyl refers to the straight chain alkynyl or branched alkynyl defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like attached at any available point to produce a stable compound.
“Alkyl alkenyl” refers to a group —R—CR′=CR′″R″″, where R is lower alkyl, or substituted lower alkyl, R′, R′″, R″″ may independently be hydrogen, halogen, lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined below.
“Alkyl alkynyl” refers to a groups —RC≡CR′ where R is lower alkyl or substituted lower alkyl, R′ is hydrogen, lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined below.
“Alkoxy” denotes the group —OR, where R is lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroalkyl, heteroarylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, or substituted cycloheteroalkyl as defined.
“Alkylthio” denotes the group —SR, —S(O)n=1−2—R, where R is lower alkyl, substituted lower alkyl, aryl, substituted aryl, aralkyl or substituted aralkyl as defined herein.
“Acyl” denotes groups —C(O)R, where R is hydrogen, lower alkyl substituted lower alkyl, aryl, substituted aryl and the like as defined herein.
“Aryloxy” denotes groups —OAr, where Ar is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl group as defined herein.
“Amino” denotes the group NRR′, where R and R′ may independently by hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined herein or acyl.
“Amido” denotes the group —C(O)NRR′, where R and R′ may independently by hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, substituted hetaryl as defined herein.
“Carboxyl” denotes the group —C(O)OR, where R is hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, and substituted hetaryl as defined herein.
“Aryl”—alone or in combination means phenyl or naphthyl optionally carbocyclic fused with a cycloalkyl of preferably 5-7, more preferably 5-6, ring members and/or optionally substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like.
“Substituted aryl” refers to aryl optionally substituted with one or more functional groups, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
“Heterocycle” refers to a saturated, unsaturated, or aromatic carbocyclic group having a single ring (e.g., morpholino, pyridyl or furyl) or multiple condensed rings (e.g., naphthpyridyl, quinoxalyl, quinolinyl, indolizinyl or benzo[b]thienyl) and having at least one hetero atom, such as N, O or S, within the ring, which can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
“Heteroaryl”—alone or in combination means a monocyclic aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing one or more, preferably 1-4, more preferably 1-3, even more preferably 1-2, heteroatoms independently selected from the group O, S, and N, and optionally substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like. Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable aromatic ring is retained. Examples of heteroaryl groups are pyridinyl, pyridazinyl, pyrazinyl, quinazolinyl, purinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrrolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazinyl, furanyl, benzofuryl, indolyl, benzothiazolyl, benzoxazolyl, and the like. A substituted heteroaryl contains a substituent attached at an available carbon or nitrogen to produce a stable compound.
“Heterocyclyl”—alone or in combination means a non-aromatic cycloalkyl group having from 5 to 10 atoms in which from 1 to 3 carbon atoms in the ring are replaced by heteroatoms of O, S or N, and are optionally benzo fused or fused heteroaryl of 5-6 ring members and/or are optionally substituted as in the case of cycloalkyl. Heterocycyl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. The point of attachment is at a carbon or nitrogen atom. Examples of heterocyclyl groups are tetrahydrofuranyl, dihydropyridinyl, piperidinyl, pyrrolidinyl, piperazinyl, dihydrobenzofuryl, dihydroindolyl, and the like. A substituted hetercyclyl contains a substituent nitrogen attached at an available carbon or nitrogen to produce a stable compound.
“Substituted heteroaryl” refers to a heterocycle optionally mono or poly substituted with one or more functional groups, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
“Aralkyl” refers to the group —R—Ar where Ar is an aryl group and R is lower alkyl or substituted lower alkyl group. Aryl groups can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
“Heteroalkyl” refers to the group —R-Het where Het is a heterocycle group and R is a lower alkyl group. Heteroalkyl groups can optionally be unsubstituted or substituted with e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
“Heteroarylalkyl” refers to the group —R-HetAr where HetAr is an heteroaryl group and R lower alkyl or substituted lower alkyl. Heteroarylalkyl groups can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, substituted lower alkyl, alkoxy, alkylthio, acetylene, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl,.nitro, cyano, thiol, sulfamido and the like.
“Cycloalkyl” refers to a divalent cyclic or polycyclic alkyl group containing 3 to 15 carbon atoms.
“Substituted cycloalkyl” refers to a cycloalkyl group comprising one or more substituents with, e.g., halogen, lower alkyl, substituted lower alkyl, alkoxy, alkylthio, acetylene, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
“Cycloheteroalkyl” refers to a cycloalkyl group wherein one or more of the ring carbon atoms is replaced with a heteroatom (e.g., N, O, S or P).
“Substituted cycloheteroalkyl” refers to a cycloheteroalkyl group as herein defined which contains one or more substituents, such as halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
“Alkyl cycloalkyl” denotes the group —R-cycloalkyl where cycloalkyl is a cycloalkyl group and R is a lower alkyl or substituted lower alkyl. Cycloalkyl groups can optionally be unsubstituted or substituted with e.g. halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
“Alkyl cycloheteroalkyl” denotes the group —R-cycloheteroalkyl where R is a lower alkyl or substituted lower alkyl. Cycloheteroalkyl groups can optionally be unsubstituted or substituted with e.g. halogen, lower alkyl, lower alkoxy, alkylthio, amino, amido, carboxyl, acetylene, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
“Optional” and “optionally” mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “optional pharmaceutical excipients” indicates that a formulation so described may or may not include pharmaceutical excipients other than those specifically stated to be present, and that the formulation so described includes instances in which the optional excipients are present and instances in which they are not.
“Treating” and “treatment” refer to any treatment of a disease in a mammal, particularly a human, and include:
(i) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;
(ii) inhibiting the disease, i.e., arresting its development; or
(iii) relieving the disease, i.e., causing regression of the disease.
All of the aforementioned embodiments include the pharmaceutically acceptable acid addition salts thereof, particularly the mono- and dihydrochlorides, and mixtures thereof.
The compounds having the general formula Ia (q=O) or Ic (q=S) can be prepared as outlined in Schemes 1-5. A general synthesis of the compounds of this invention is outlined in Scheme 1. Compound IV can be prepared by N-acylation of substituted aniline II with 2-substituted chloroacetylchloride III. Compound II is available commercially or readily prepared through reduction of the corresponding nitrobenzene derivative (acid/SnCl2 or catalytic hydrogenation, see Advanced Organic Chemistry, Ed. J. March, (1992) A. Wiley-Interscience). Some examples of commercially available substituted anilines corresponding to general structure II include 2,6-dimethylaniline, 2,3-dimethylaniline, 2-methylaniline, 4-methylaniline, 4-methylaniline, 2,4-dichloroaniline, 3,4-dichloroaniline, 2,5-dichloroaniline, 2,4-dichloroaniline, 2-chloroaniline, 3-chloroaniline, 2,6-difluoroaniline, 2,5-difluoroaniline, 3,4-difluoroaniline, 2-fluoroaniline, 4-fluoroaniline, 3-fluoroaniline, 2-fluoro-6-chloroaniline, 4-fluoro-3-chloroaniline, 4-acetoxyaniline.
Figure US06573264-20030603-C00004
Compound VI can be obtained by reacting compound IV with N-protected substituted piperazine V through warming in an appropriate solvent (e.g. DMF, EtOH). Protection of the nitrogen of compound V is only required when it is useful to control the regiochemistry of the addition of Compound V with compound IV. In some cases, compound V can be obtained from commercial resources. Examples of commercially available compounds corresponding to general structure V include 2-methylpiperazine, 2,5-dimethylpiprazine, 2,6-dimethylpiperazine, 2,3,5,6-tetramethylpiperazine, piperazine-2-carboxylic acid, perhydroquinoxaline, 2-aminomethyl-6-methylpiperazine, 2-aminomethylpiperazine, 2-(o-chlorophenyl)piperazine, and 2-(m-chlorophenyl)piperazine. Deprotection of compound VI can be accomplished using the standard conditions (e.g. for Boc group use TFA, for CBZ and benzyl use hydrogenation). Compound Ia or Ic can be prepared by reacting compound VII with epoxide VIII through warming in an appropriate solvent (ethanol, DMF, CHCl2, THF) or by stirring at room temperature in the presence of a lanthamide (III) Lewis acid (Chini, M et al., Tetrahedron Lett., 35: 433-36 (1994).
Figure US06573264-20030603-C00005
Epoxide VIII (where m=1, 2, or 3) can be prepared as outlined in Scheme 2. Heating substituted phenol, or thiophenol IX with epichlorohydrin, epibromohydrin, or 4-bromo-1,2-epoxybutane and potassium carbonate in acetone or sodium hydride in DMF can afford epoxide VIII. Compound IX can be obtained from commercial resources. Examples of commercially available compounds corresponding to structure XI include 2-methyl-5-hydroxybenzothiazole, 2-hydroxybenzothiazole, 8-hydroxyquinolidine, 6-hydroxyquinoline, 4-hydroxyquinoline, 5-hydroxyisoquinoline, 3-hydroxypyridine, 2-quinoxalinol, and 4-(imidazol-1-yl)phenol. In some cases compound VIII can be obtained from commercial sources. Examples of commercially available compounds corresponding to general structure VIII include 4-glycidyloxy-2-indolecarboxamide.
Compound IX can in turn be prepared by the deprotection of the corresponding methyl or benzyl ethers (X) using Lewis acids as shown in Scheme 3 (BBr3, BF3, etc.—see Advanced Organic Chemistry, Ed. J. March (1992) A. Wiley Intersciences, p 434). Benzyl ethers can also be deprotected by refluxing with palladium hydroxide in ethanol/cyclohexene (see Catalytic hydrogenation over platinum metals, P. N. Rylander, Academic Press, New York, N.Y., (1976) p 464). Commercially available methyl ethers include 6-methoxy-2-methyl-benzothiazole.
Figure US06573264-20030603-C00006
Compound IX can also be prepared by the diazotization of the corresponding amino compounds (XI) as shown in Scheme 4 (Boggust, W. A and Cocker, W. J. Chem. Soc. 1949, 355). Commercially available amines include 6-amino-benzothiazole.
Figure US06573264-20030603-C00007
The 6, 5 fused ring system of compound X can be prepared by the cyclization of commercially available ethers of 2-aminophenols, 2-aminothiophenols, or 2-aminoanilines (XII) with orthoesters (XIII) (Musser, J. H. et al., J. Med. Chem. 1985, 28, 1255-1259) or imidates (XIV) (Gregory, G. I. Et al., J. Chem. Soc. Perkin Trans. 1, 1973, 47-51) as shown in Scheme 5 and 6 respectively. Commercially available, ethers of aminophenols include 4-methoxy-2-aminophenol, orthoesters include trimethyl orthoformate and trimethyl orthoacetate, imidates include ethyl acetimidate hydrochloride, and ethyl benzimidate hydrochloride.
Figure US06573264-20030603-C00008
Figure US06573264-20030603-C00009
The thiophenol analog of compound XII can be prepared from the commercially available compound XV by reacting with sodium disulfide hydrate followed by reduction using tin and hydrochloric acid ( Dannley, R. L. and Zazaris, D. A; Can. J. Chem. 1965, 43, 2610-2612) as shown in Scheme 7. Commercially available nitro compounds include 3-nitro-4-chloroanisole.
Figure US06573264-20030603-C00010
Imidate XIV can be prepared by bubbling HCI gas through an alcoholic solution of the commercially available nitrites XVI as shown in Scheme 8. Commercially available nitriles include, benzonitrile, 4-trifluoromethylbenzonitrile and 3-trifluoromethylbenzonitrile.
Figure US06573264-20030603-C00011
Sulfur containing 6,5 fused ring system of compound X can also be prepared from the commercially available ethers of anilines XVII (Stevens, M. F. G. et al, J. Med. Chem. 1994, 37, 1689-1695) as shown in Scheme 9. Thioamide XX can be obtained by the reaction of Lawesson's reagent with amide XIX which in turn can be prepared by the reaction of compound XVII with compound XVIII. Cyclization of XX with potassium ferrocyanide under basic conditions can afford compound XXI. Commercially available ethers of anilines include benzyloxyanilines and anisidines.
Figure US06573264-20030603-C00012
A general synthesis of the compound XXV of this invention is outlined in Scheme 10. Compound XXIV can be prepared by the deprotection of compound XXIII using the standard conditions (e.g. for BOC group use TFA, for CBZ and benzyl use hydrogenation). Compound XXIII in turn can be prepared by the reaction of the commercially available protected monoketopiperazine analog compound XXII with compound IV and sodium hydride in an appropriate solvent (DMF, THF). An example of the commercially available monoketopiperazines include 4-benzyloxycarbonylpiperazine-2-one.
Figure US06573264-20030603-C00013
A general synthesis of the compound Ib (q=NH) of this invention is outlined in Schemes 11 and 12. Compound XXVII can be prepared by refluxing compound VII with the epoxide XXVI in a suitable solvent (ethanol, THF). Deprotection of compound XXVII can be accomplished by using standard conditions (e.g. for BOC group use TFA; for CBZ use hydrogenation or Pd(OH)2). Compound Ib can be prepared by refluxing compound XXVIII with compound XXIX in a suitable solvent (ethanol, THF). Commercially available compound XXIX includes 2-chlorobenzothiazole, 2-chlorobenzoxazole, 2-chloropyridine, 2-chloropyrimidine, 2-chloro-4-(trifluoromethyl)pyrimidine, and chloropyrazine.
Figure US06573264-20030603-C00014
Epoxide XXVI in turn can be prepared as shown in Scheme 12. Commercially available compound XXX can be protected using the standard conditions (for BOC protection use BOC anliydride; for CBZ protection use CBZ-Cl). Compound XXV can be prepared by the reaction of compound XXXI using m-chloroperbenzoic acid in a suitable solvent (e.g. dichloromethane). An example of a commercially available compound XXX includes by is not limited to allylamine.
Figure US06573264-20030603-C00015
Compound V can be prepared as described in Scheme 13. Alkylation of compound XXXII with alkyl halides using t-BuLi as base can afford compound XXXIII as described by Pohlman et. al. (J. Org. Chem, 1997, 62, 1016-1022). Reduction of XXXIV using diborane can afford the N-benzyl protected version of compound V after N-Boc deprotection with trifluoroacetic acid (TFA) [for the diborane reduction see Jacobson et. al, J. Med. Chem, 1999, 42, 1123-1144].
Figure US06573264-20030603-C00016
Compound V can also be prepared through standard coupling (eg. EDC or PyBroP) of D or L amino acids and standard deprotection as outlined in Scheme 14 (Cledera, P. et al. Tetrahedron, 1998 p. 12349-12360; Smith, R. A. et al Bioorg. Med. Chem. Lett. 1998, p. 2369-2374). Reduction of the diketopiperazine XXXVII with diborane can afford the N-benzyl protected version of compound V.
Figure US06573264-20030603-C00017
Compound V can also be prepared as described in Scheme 15. Bromination of aldehydes XXXVIII followed by the reaction with ethylene diamine can afford the imine XLI. Catalytic hydrogenation of compound XLI can afford compound V (Bogeso, K. P., et al, J. Med. Chem. 1995, 38, p 4380-4392). Commercially available aldehydes include isobutyraldehyde.
Figure US06573264-20030603-C00018
Compound V also includes the bicyclic homologs of piperazine (1S,4S)-(+)-2,5-diazabicyclo[2.2.1]heptane 83, 3,8-diazabicyclo[3.2.1] octane 84, and 2,5-diazabicyclo[2.2.2] octane 85.
Figure US06573264-20030603-C00019
Commercially available bicyclic analogs include (1S,4S)-(+)-2,5-diazabicyclo[2.2.1]heptane 83. Compounds 84, 85, and the (1R,4R) isomer of 83 can be prepared by published procedures (for 84 and 85- see Sturm, P. A. et al, J. Med. Chem. 1974, 17, 481-487; for 83 see—Barish, T. F. and Fox, D. E. J. Org. Chem., 1990, 55, 1684-1687).
Specific examples of the preparation of compounds corresponding to the general schemes described above are disclosed in Scheme 16-29 of the Examples which further illustrate alternative methods for preparing compounds of this invention. In particular, 2,6-methylaniline was acylated with 2-chloroacetyl chloride 2 using saturated bicarbonate and ether (1:1) as base and co-solvent, respectively to afford the chloroacetamide derivative 3. Further reaction of compound 3 with piperazine afforded compound 5 through warming in ethanol. Reaction of compound 5 with epoxide 6 by warming both components in ethanol at reflux afforded piperazine derivative 7 as illustrated in Scheme 16. Compound 6 was prepared by warming epichlorohydrin with the phenol 8 in acetone in the presence of K2CO3 as described in Scheme 17.
Figure US06573264-20030603-C00020
Figure US06573264-20030603-C00021
The benzoxazole derivative 8 was prepared by the deprotection of compound 13 as shown in Scheme 18. Compound 10 was prepared by condensation of 2-amino-4-methoxyphenol 12. Compound 12 was obtained by the catalytic hydrogenation of the commercially available 4-methoxy-2-nitrophenol 11, and the benzimidate derivative 13 as shown in Scheme 19. Compound 13 was obtained from 3-trifluoromethylbenzonitrile 14 using a Pinner reaction (ethanoluanhydrous HCl).
Figure US06573264-20030603-C00022
Figure US06573264-20030603-C00023
SCHEME 20
Synthesis of the key intermediates that were used in the preparation of the compounds described in this invention are shown in Scheme 21-25. Compound 16 was prepared by the diazotization of the commercially available 6-aminobenzothiazole as shown in scheme 21.
Figure US06573264-20030603-C00024
Compound 19 was prepared by condensation of compound 12 with trimethyl orthoacetate 18 as shown in Scheme 22.
Figure US06573264-20030603-C00025
Compound 22 can be prepared by the reduction of compound 21 with tin and hydrochloric acid as shown in Scheme 23. Compound 21 was synthesized by reacting compound 20 with sodium disulfide hydrate.
Figure US06573264-20030603-C00026
Compound 26 was prepared by the reaction of compound 25 with Lawesson's reagent as shown in Scheme 24. Compound 25 was prepared by the reaction of the aniline 23 with benzoyl chloride 24. Cyclization of the thioamide 26 with potassium ferrocyanide in aqueous sodium hydroxide gave a mixture of compounds 27 and 28. Compounds 27 and 28 were separated by column chromatography.
Figure US06573264-20030603-C00027
Debenzylation of compound 27 was carried out as shown in Scheme 25 by transfer hydrogenolysis using Pearlmann's catalyst in ethanol/cyclohexene.
Figure US06573264-20030603-C00028
Synthesis of compound 34 of this invention is described in Scheme 26. The amide 3 was prepared as described in Scheme 16. Reaction of 3 with the manion of the anion of the monoketopiperazine 30 formed through treatment with sodium hydride in DMF gave compound 31. Compound 34 was obtained through warming compound 32 with the epoxide 33 in ethanol. Compound 32 was prepared by the deprotection of compound 31 by catalytic dehydrogenation. Epoxide 33 was prepared in the same manner as compound 6 described in Scheme 17.
Figure US06573264-20030603-C00029
Synthesis of a specific compound 39 of this invention is described in Scheme 27. The synthesis of compound 5 was described previously (Scheme 16). Warming compound 5 to reflux with the epoxide 35 in ethanol gave compound 36. Deprotection of 36 by treatment with palladium hydroxide in ethanol/cyclohexene under reflux conditions gave the amine 37. The final compound 39 was prepared by reacting 37 with 2-chlorobenzothiazole in ethanol and triethylamine.
Figure US06573264-20030603-C00030
Epoxide 35 was synthesized as described in Scheme 28. Allylamine 40 was reacted with benzyl chloroformate in dichloromethane to afford compound 42. Reaction of m-chloroperbenzoic acid with 42 gave the epoxide 35.
Figure US06573264-20030603-C00031
The acid addition salts of the compounds of this invention may be converted to the corresponding free base by treating with a suitable base, such as potassium carbonate or sodium hydroxide, typically in the presence of aqueous solvent, and at a temperature of between about 0 degrees C. and 100 degrees C. The free base form is isolated by conventional means, such as extraction with an organic solvent.
Salts of the compounds of this invention may be interchanged by taking advantage of differential solubilities and volatilities, or by treating with the appropriately loaded ion exchange resin. This conversion is carried out at a temperature between about 0° C. and the boiling point of the solvent being used as the medium for the procedure. Administration of the active compounds and salts described herein can be via any of the accepted modes of administration for therapeutic agents. These methods include oral, parenteral, transdermal, subcutaneous and other systemic modes. The preferred method of administration is oral, except in those cases where the subject is unable to ingest, by himself, any medication. In those instances it may be necessary to administer the composition parentarally.
Depending on the intended mode, the compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages. The compositions may include one or more conventional pharmaceutical excipients and at least one active compound of this invention or the pharmaceutically acceptable salts thereof and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.
The amount of active compound administered will, of course, be dependent on the subject being treated, the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. However, an effective dosage is in the range of 0.1-30 mg/kg/day, preferably 0.5-20 mg/kg/day. For an average 70 kg human, this would amount to 7-2100 mg per day, or preferably 35-1400 mg/day. Since many of the effects of the compounds herein (protect skeletal muscles against damage resulting from trauma; protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication; treat shock conditions; preserve donor tissue and organs used in transplants; and treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, exercise induced angina, congestive heart disease, and myocardial infarction) are achieved through a similar mechanism (partial fatty acid oxidation inhibition) dosages (and forms of administration) are all generally within the same general and preferred ranges for all these utilities.
For solid compositions, conventional non-toxic solid include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, for example, propylene glycol, as the carrier. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a quantity of the active compound(s), a therapeutically effective amount, i.e. in an amount effective to alleviate the symptoms of the subject being treated. For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain 10%-95% active ingredient, preferably 1-70%.
Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
A more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained. See, e.g., U.S. Pat. No. 3,710,795, which is incorporated herein by reference. In another recent approach, the compositions of this invention can be administered orally in a sustained release dosage form using the compositions and/or methods disclosed in U.S. patent application Ser. No. 09/321,522, filed on May 27, 1999, the specification of which is incorporated herein by reference.
It is within the scope of this invention to administer one or more compounds of this invention to a mammal, and preferably to a human by other known routes of pharmaceutical dosage form administration including, but not limited to by bolus, intravenously, transdermally, through inhalation, sub-cutaneously, or any other therapeutic agent administration method or route know to one skilled in the art.
The following Examples are representative of the invention, but are not to be construed as limiting the scope of the claims.
EXAMPLE 1 N-(2,6-Dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)benzoxazol-5-yloxyl-propyl}-piperazin-1-yl)acetamide (7)
Figure US06573264-20030603-C00032
Part A.
Synthesis of N-(2,6-Dimethylphenyl)-2-chloroacetamide (3):
2,6-dimethylaniline (9.8 g, 81.2 mmol) was dissolved in ether (100 mL) and saturated aqueous NaHCO3 (100 mL) and the reaction mixture was cooled in an ice/water bath. To the cold solution was added chloroacetyl chloride 2 (9.17 g, 81.2 mmol) dropwise over a period of 2 h. The mixture was allowed to warm to RT over 14 h. The mixture was extracted with ethyl acetate (3×50). The combined organic layers were dried over MgSO4, filtered, and concentrated. The residue was triturated in ether and filtered to afford compound 3 as a white solid.
Part B.
Synthesis of N-(2,6-Dimethylphenyl)-piperazin-1-yl-acetamide (5):
To a solution of compound 3 (5 g, 25.2 mmol) in ethanol (100 mL) was added piperazine 4 (2.1 g, 25.0 mmol) and N,N-diisopropylethylamine (3.2 g, 25.2 mmol). The reaction mixture was refluxed for 24 h. The mixture was concentrated in vacuo and the residue was purified by column chromatography (10:1 DCM: MeOH) to afford compound 5.
Part C.
Synthesis of 5-(Oxiran-2-yl-methoxy)-2-1(3-trifluoromethyl)phenyl]benzoxazole (6):
1. Synthesis of 2-Amino4-methoxyphenol (12):
A solution of 4-methoxy-2-nitrophenol 11 (10 g, 59.1 mmol) and Pd/C (1.0 g) in methanol (100 ml) was placed on a Parr shaker under H2 (50 psi) for 60 minutes. The reaction mixture was filtered through Celite 521 and the filter cake washed with MeOH. The filtrate was evaporated (in vacuo), to yield compound 12 as a tan solid.
2. Synthesis of 3-Trifluoromethyl-benzimidic Acid Ethyl Ester Hydrochloride (13):
To a solution of α,α,α-trifluoromethyl-m-tolunitrile 14 (1 g, 5.84 mmol) in EtOH (10 mL, anhydrous) was bubbled HCl (gas, anhydrous) for 10 minutes and the solution was stirred overnight. The solvent was evaporated to yield compound 13 as a white solid. The resulting solid was used in the next step without purification.
3. Synthesis of 5-Methoxy-2-(3-trifluoromethylphenyl)-benzoxazole (10):
A solution of compound 13 and compound 12 (850 mg, 6.13 mmol) in THF (10 mL) was heated to reflux and allowed to stir overnight. The reaction mixture was allowed to cool and the THF evaporated (in vacuo). The residue was dissolved in ethyl acetate and washed with water. The organic layer was dried over MgSO4 and treated with activated carbon Norit A. The mixture was filtered through Celite 521, and evaporated (in vacuo) and the residue was purified using column chromatography (20% Ethyl acetatelhexanes) to afford compound 10 as a light yellow solid.
4. Synthesis of 2-[(3-Trifluoromethyl)phenyl]benzoxazol-5-ol (8):
To a solution of compound 10 (200 mg, 0.68 mmol) in CH2Cl2 (5 mL) was added BBr3 (1M in CH2Cl2, 1 mL, 1 mmol) dropwise. The resulting solution was allowed to stir for 48 h. The solvent was removed by evaporation (in vacuo) and the residue was dissolved in ethyl acetate and washed with saturated NaHCO3. The organic layer was dried over MgSO4 and evaporated (in vacuo). The residue was purified using column chromatography (30% ethyl acetate/hexanes) to yield compound 8 as a white solid.
5. Synthesis of 5-(Oxiran-2-yl-methoxy)-2-[(3-trifluoromethyl)phenyl]benzoxazole (6):
To a suspension of NaH (7 mg, 60% dispersion in oil, 0.18 mmol) in DMF (2 mL, anhydrous) was added a solution of compound 8 (54 mg, 0.19 mmol) in DMF (2 mL, anhydrous) dropwise. The solution was allowed to stir for 15 minutes. To the above solution epichlorohydrin (50 μL, 0.63 mmol) was added and the resulting solution was allowed to stir overnight. The solvent was evaporated (in vacuo) and the residue dissolved in water and extracted with ethyl acetate. The organic layers were combined, dried over MgSO4 and evaporated to yield compound 6 as a clear oil.
Part D.
Synthesis N-(2,6-Dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide (7):
A solution of compound 5 (183 mg, 0.73 mmol) and compound 6 in EtOH (2 mL) and triethylamine (0.2 mL) was heated to 90° C. and allowed to stir overnight. The reaction mixture was allowed to cool and the solvent evaporated (in vacuo) to yield an oil. The oil was purified by prep TLC (5/0.5/94.5 MeOH/NH4OH/CH2Cl2) to yield compound 7 as a white Solid: Mass Spectrum (MH+)=583.4
EXAMPLE 2 2-{4-13-(Benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethylphenyl)acetamide (43)
Figure US06573264-20030603-C00033
Synthesis of 2-(Oxiran-2-ylmethoxy)benzothiazole (44)
Figure US06573264-20030603-C00034
Compound 44 was prepared in the manner of compound 6 substituting 2-hydroxy-benzothiazole for compound 8 in partC-5 of Example 1.
Compound 43 was prepared in the manner of compound 7 substituting compound 44 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=455.3.
EXAMPLE 3 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide (45)
Figure US06573264-20030603-C00035
Synthesis of 2-Methyl-5-(oxiran-2-ylmethoxy)benzothiazole (33):
Figure US06573264-20030603-C00036
Compound 33 was prepared in the manner of compound 6 substituting 2-methyl-benzothiazol-5-ol for compound 8 in partC-5 of Example 1.
Compound 45 was prepared in the manner of compound 7 substituting compound 33 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=469.3
EXAMPLE 4 4-(3-{4-1(2,6-Dimethylphenylcarbamoyl)-methyl-piperazin-1-yl}-2-hydroxy-propoxy)-1H-indole-2-carboxylic acid amide (46)
Figure US06573264-20030603-C00037
Compound 19 was prepared in the manner of compound 7 substituting the commercially available 4-glycidyloxy-2-indolecarboxamide for compound 6 in part D of compound 7: Mass Spectrum (MH+)=480.4.
EXAMPLE 5 2-{4-[3-(Benzothiazol-6-yloxy)2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6dimethyl-phenyl)-acetamide (47)
Figure US06573264-20030603-C00038
Synthesis of Benzothiazol-6-ol (16)
Figure US06573264-20030603-C00039
To a solution of 6-aminobenzothiazole (1.0 g, 6.66 mmol) in water (22 mL) and H2SO4 (16 mL) at 5° C. was added a solution of sodium nitrite (460 mg, 6.72 mmol) in water (13 mL) keeping the temperature below 5° C. The resulting solution was allowed to stir for 15 minutes. The reaction mixture was heated to 160° C. and a solution of H2SO4 (50 mL) and water (38 mL) was slowly added. The resulting mixture was allowed to stir for 1 h. The mixture was allowed to cool and an aqueous solution of 50% sodium hydroxide was added until the pH=7. The mixture was extracted with ethyl acetate and washed with brine. The combined organic was dried over MgSO4 and evaporated to yield a semi-solid. The semi-solid was purified by column chromatography (40% ethyl acetate/hexanes) to yield benzothiazo-6-ol 16 as an off-white solid.
Synthesis of 6-(Oxiran-2-ylmethoxy)benzothiazole (48)
Figure US06573264-20030603-C00040
Compound 48 was prepared in the manner of compound 6 substituting compound 16 for compound 8 in partC-5 of Example 1.
Compound 47 was prepared in the manner of compound 7 substituting compound 48 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=455.3.
EXAMPLE 6 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-6-yloxy)-propyl]-piperazin-1-yl}aceamide (49)
Figure US06573264-20030603-C00041
Synthesis of 2-Methylbenzothiazol-6-ol (50)
Figure US06573264-20030603-C00042
Compound 50 was prepared from the commercially available 6-methoxy-2-methyl-benzothiazole as described in partC-4 of Example 1.
Synthesis of 2-Methyl-6-(oxiran-2-ylmethoxy)benzothiazole (51)
Figure US06573264-20030603-C00043
Compound 51 was prepared in the manner of compound 6 substituting compound 50 for compound 8 in partC-5 of Example 1.
Compound 49 was prepared in the manner of compound 7 substituting compound 51 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=469.3.
EXAMPLE 7 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-3,5-dimethyl-piperazine-1-yl}acetamide (52)
Figure US06573264-20030603-C00044
Synthesis of N-(2,6-Dimethylphenyl)-2-C3,5-dimethylpiperazin-1-yl)acetamide (53)
Figure US06573264-20030603-C00045
Compound 53 was prepared in the manner of compound 3 substituting 2,6-dimethylpiperazine for piperazine in part A of Example 1.
Compound 52 was prepared in the manner of compound 7 substituting compound 33 for compound 6 and compound 53 for compound 5 in part D of compound 7: Mass Spectrum (MH+)=497.4.
EXAMPLE 8 2-{4-[2-Hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-N-(4-hydroxy-phenyl)acetamide (54)
Figure US06573264-20030603-C00046
Synthesis of 4-Aminophenyl Acetate (55)
Figure US06573264-20030603-C00047
Compound 55 was prepared in the manner of compound 12 substituting 4-nitrophenyl acetate for compound 11 in part C-1 of Example 1.
Synthesis of 4-(2-Chloroacetylamino)phenyl Acetate (56)
Figure US06573264-20030603-C00048
Compound 56 was prepared in the manner of compound 3 substituting compound 55 for compound 1 in part A of Example 1.
Synthesis of 4-(2-Piperazinylacetylamino)phenyl Acetate(57)
Figure US06573264-20030603-C00049
Compound 57 was prepared as described in part B of Example 1 substituting compound 56 for compound 3.
Compound 54 was prepared in the manner of compound 7 substituting compound 33 for compound 6 and compound 57 for compound 5 in part D of compound 7: Mass Spectrum (MH+)=457.5.
EXAMPLE 9 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide (58)
Figure US06573264-20030603-C00050
Synthesis of Phenyl-N-13-(phenylmethoxy)phenyl]carboxamide (25)
Figure US06573264-20030603-C00051
To a solution of 3-benzyloxyaniline 23 (1.0 g, 5.0 mmol) and TEA (0.74 mL, 5.3 mmol) in CH2Cl2 was added benzoyl chloride (0.61 mL, 5.26 mmol) dropwise and the mixture was allowed to stir overnight. The reaction mixture was diluted with water and the resulting solid was collected by vacuum filtration. The solid was allowed to air dry, to yield compound 25 as a white solid.
Synthesis of Phenyl{[(3-phenylmethoxy)phenyl]amino}methane-1-thione (26)
Figure US06573264-20030603-C00052
A solution of compound 25 (455 mg, 1.5 mmol) and Lawesson's reagent (0.6 mol equiv) in chlorobenzene (15 mL) was heated to 120° C. and allowed to stir for 1.5 h. The reaction was allowed to cool and the solvent was evaporated (in vacuo). The residue was purified by column chromatography (ethyl acetate/hexane 1:9) to yield compound 26 as a yellow solid.
Synthesis of 2-Phenyl-5-(phenylmethoxy)benzothiazole (27)
Figure US06573264-20030603-C00053
To a solution of compound 26 (960 mg, 3 mmol) in ethanol (5 mL) was added an aqueous sodium hydroxide solution (30%, 8 mol equiv). The mixture was diluted with water (6 mL) to give a final solution of 10% aqueous sodium hydroxide. The resulting solution was added to a stirred solution of potassium ferricyanide (4 mol equiv) in water at 90° C. in aliquots (1 mL) and the resulting mixture was heated for 30 min. The reaction mixture was allowed to cool and the product was extracted with ethyl acetate. The organic layer was dried and evaporated. The residue, a mixture of 27 and 28, was column purified (ethyl acetate/hexane—1:99) to provide compound 27 as a white solid.
Synthesis of 2-Phenylbenzothiazol-5-ol (29)
Figure US06573264-20030603-C00054
Palladium hydroxide (100 mg) was added to a solution of 27 (260 mg, 0.8 mmol) of ethanol/cyclohexene (5 mL/2 mL) followed by warming for reflux for 16 h. The reaction mixture was cooled and the catalyst was removed by filtration (through Celite). The solvent was evaporated to provide compound 29 as a white solid.
Synthesis of 5-(Oxiran-2-ylmethoxy)-2-phenylbenzothiazole (59)
Figure US06573264-20030603-C00055
Compound 59 was prepared in the manner of compound 6 substituting compound 29 for compound 8 in partC-5 of Example 1.
Compound 58 was prepared in the manner of compound 7 substituting compound 59 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=531.6
EXAMPLE 10 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide (60)
Figure US06573264-20030603-C00056
Synthesis of 5-(Oxiran-2-ylmethoxy)-2-phenylbenzoxazole (61)
Figure US06573264-20030603-C00057
Compound 61 was prepared in the manner of compound 6 substituting ethyl benzimidate hydrochloride for compound 13 in partC 1-5 of Example 1.
Compound 60 was prepared in the manner of compound 7 substituting compound 61 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=515.3.
EXAMPLE 11 N-(2,6-Dimethylphenyl)2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-7-yloxy)-propyl]-piperazin-1-ylacetamide (62)
Figure US06573264-20030603-C00058
Synthesis of 7-(Oxiran-2-ylmethoxy)-2-phenylbenzothiazole (63)
Figure US06573264-20030603-C00059
Compound 63 was prepared in the manner of compound 59 substituting deprotected compound 28 for compound 29 in example 9.
Compound 62 was prepared in the manner of compound 7 substituting compound 63 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=531.3.
EXAMPLE 12 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-2-oxo-piperazin-1-yl}acetamide (64)
Figure US06573264-20030603-C00060
Synthesis of Phenylmethyl 4-{[N-(2,6-Dimethylphenyl)carbamoyl]methyl}-3-oxopiperazinecarboxylate (31)
Figure US06573264-20030603-C00061
To a solution of compound 30 (252 mg, 1.3 mmol) in THF (13 mL) and NaH (62 mg, 1.6 mmol) was added Compound 3 (300 mg, 1.3 mmol). The solution was allowed to stir under nitrogen overnight. The reaction was quenched with water (0.1 mL) and dried over Na2SO4 The solution was concentrated and purified using column chromatography conditions to yield compound 31 as a solid.
Synthesis of N-(2,6-Dimethylphenyl)-2-(2-oxopiperazinyl)-acetamide (32)
Figure US06573264-20030603-C00062
To a solution of compound 31 in methanol (10 mL) 10% palladium on carbon was added. The reaction vessel was charged with hydrogen (40 p.s.i ) and agitated for 4 h. The catalyst was removed by filtration and the filtrate was concentrated and purified using column chromatography (1:15 MeOH:DCM) to yield compound 32 as a semi solid.
Compound 64 was prepared in the manner of compound 7 substituting compound 33 for compound 6 and compound 32 for compound 5 in part D of compound 7: Mass Spectrum (MH+)=483.3
EXAMPLE 13 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide (65)
Figure US06573264-20030603-C00063
Synthesis of 5-Methoxy-2-methyl-benzoxazole (19)
Figure US06573264-20030603-C00064
A solution of 2-amino-4-methoxyphenol 17 (8 g, 57.4 mmol) in trimethyl orthoacetate 18 (50 mL) was heated to reflux and allowed to stir for 24 h. The reaction was allowed to cool and the excess 18 was evaporated (in vacuo). The residue was dissolved in ethyl acetate and washed with water. The organic layer was dried over MgSO4 and treated with activated carbon Norit A. The resulting solution was filtered through Celite 521 and evaporated to yield an oil. The oil was chromatographed on silica gel (20% ethyl acetateihexanes) to yield compound 19 as a light yellow solid.
Synthesis of 2-Methyl-5-oxiran-2-ylmethoxybenzoxazole (67)
Figure US06573264-20030603-C00065
Compound 67 was prepared in the manner of compound 6 substituting 6-hydroxy-2-methyl-benzoxazole 66 for compound 8 in part C-5 of Example 1.
Compound 66 in turn was obtained by the deprotection of compound 19 as described in partC-4 of Example 1.
Compound 65 was prepared in the manner of compound 7 substituting compound 67 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=543.4
EXAMPLE 14 N-(2,6-Dimethylphenyl)-2-(4-{2-hydroxy-3-12-(4-trifluoromethyl-phenyl)-benzoxazol-5-yloxyl-propyl}-piperazin-1-yl)acetamide (68)
Figure US06573264-20030603-C00066
Synthesis of 5-(Oxiran-2-ylmethoxy)-2-(4-trifluoromethyl-phenyl)benzoxazole (69)
Figure US06573264-20030603-C00067
Compound 69 was prepared in the manner of compound 6 substituting 4-trifluoromethylbenzimidic acid ethyl ester hydrochloride for compound 13 in partC1-5 of Example 1.
Compound 68 was prepared in the manner of compound 7 substituting compound 69 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=583.4
EXAMPLE 15 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(quinoxalin-2-yloxy)-propyl]-piperazin-1-yl}acetamide (70)
Figure US06573264-20030603-C00068
Synthesis of 2-(Oxiran-2-ylmethoxy)quinoxaline (71)
Figure US06573264-20030603-C00069
Compound 71 was prepared in the manner of compound 6 substituting quinoxaline-2-ol for compound 8 in part C-5 of Example 1.
Compound 70 was prepared in the manner of compound 7 substituting compound 71 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=450.9.
EXAMPLE 16 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(pyridin-3-yloxy)-propyl]-piperazin-1-yl}acetamide (72)
Figure US06573264-20030603-C00070
Synthesis of 3-(Oxiran-2-ylmethoxy)pyridine (73)
Figure US06573264-20030603-C00071
Compound 73 was prepared in the manner of compound 6 substituting 3-hydroxy-pyridine for compound 8 in part C-5 of Example 1.
Compound 72 was prepared in the manner of compound 7 substituting compound 73 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=399.4.
EXAMPLE 17 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin4-yloxy)-propyl]-piperazin-1-yl}acetamide (74)
Figure US06573264-20030603-C00072
Synthesis of 4-(Oxiran-2-ylmethoxy)quinoline (75)
Figure US06573264-20030603-C00073
Compound 75 was prepared in the manner of compound 6 substituting 4-hydroxy-quinoline for compound 8 in part C-5 of Example 1.
Compound 74 was prepared in the manner of compound 7 substituting compound 75 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=449.4.
EXAMPLE 18 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propyl]-piperazin-1-yl}acetamide (76)
Figure US06573264-20030603-C00074
Synthesis of 5-(Oxiran-2-ylmethoxy)isoquinoline (77)
Figure US06573264-20030603-C00075
Compound 77 was prepared in the manner of compound 6 substituting 5-hydroxy-isoquinoline for compound 8 in part C-5 of Example 1.
Compound 76 was prepared in the manner of compound 7 substituting compound 77 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=449.4.
EXAMPLE 19 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propyl]-piperazin-1-yl}acetamide (78)
Figure US06573264-20030603-C00076
Synthesis of 6-(Oxiran-2-ylmethoxy)quinoline (79)
Figure US06573264-20030603-C00077
Compound 79 was prepared in the manner of compound 6 substituting 6-hydroxy-quinoline for compound 8 in part C-5 of Example 1.
Compound 78 was prepared in the manner of compound 7 substituting compound 79 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=449.4
EXAMPLE 20 N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-quinolin-7-yloxy)-propyl]-piperazin-1-yl}acetamide (80)
Figure US06573264-20030603-C00078
Synthesis of 2-Methyl-7-(oxiran-2-ylmethoxy)quinoline (81)
Figure US06573264-20030603-C00079
Compound 81 was prepared in the manner of compound 6 substituting 7-hydroxy-2-methyl-quinoline for compound 8 in part C-5 of Example 1.
Compound 80 was prepared in the manner of compound 7 substituting compound 81 for compound 6 in part D of compound 7: Mass Spectrum (MH+)=463.5.
EXAMPLE 21 2-{4-[3-(Benzothiazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide (39)
Figure US06573264-20030603-C00080
Synthesis of (Phenylmethoxy)-N-prop-2-enylcarboxamide (42)
Figure US06573264-20030603-C00081
To a solution of allylamine (3.34 g, 5.85 mmol) in dichloromethane (100 mL) and triethylamine (16 mL) benzyl chloroformate (8.25 mL, 5.78 mmol) was added at 0° C. The mixture was stirred at 0° C. for 2 hours and additional 90 minutes at RT. The solvent was removed by evaporation and the residue was purified by flash column chromatography (30% EtOAc/Hexanes) to yield compound 42 as a clear oil.
Synthesis of N-(Oxiran-2-ylmethoxy)(phenylmethoxy)carboxamide (35)
Figure US06573264-20030603-C00082
Compound 42 (5.0 g, 2.61 mmol) was treated with m-chloroperbenzoic acid (11.71 g, 9.1 mmol) in dichloromethane (110 mL) at room temperature for 18 h. Dichloromethane was evaporated to afford a viscous oil which was then purified by flash column chromatography (30%EtOAc/Hexanes) to give compound 35 as a clear oil.
Synthesis of N-(2,6-Dimethylphenyl)-2-(4-{2-hydroxy-3 -[phenylmethoxyl carbonylaminol propyl}piperazinyl)acetamide (36)
Figure US06573264-20030603-C00083
A solution of compound 42 (2.5 g, 1.2 mmol) and compound 5 (5.94 g, 2.4 mmol) in ethanol (100 mL) and triethylamine (3.34 mL) was refluxed for 18 h. Solvents were removed and the residue was purified by flash column chromatography (ethyl acetate) to afford compound 36 as a white solid.
Synthesis of 2-[4-(3-Amino-2-hydroxypropyl)piperazinyl]-N-(2,6-dimethylphenyl)acetamide (37)
Figure US06573264-20030603-C00084
A solution of compound 36 (3.0 g, 0.66 mmol) in methanol (70 mL) in presence of 10% Palladium on Carbon (0.337 g) was stirred under hydrogen atmosphere for 16 h. Filtration of catalyst followed by concentration afforded compound 37 as a sticky solid.
To a solution of compound 37 (75 mg) in ethanol (2 mL) was added triethylamine (0.13 mL) and 2-chlorobenzthiazole (87 mg) followed by warming to reflux for 16 h. The reaction mixture was concentrated and purified by preparative TLC (5%MeOH/Dichloromethane) to give Compound 39 as a white solid. Mass Spectrum (MH+)=454.4.
EXAMPLE 22 2-{4-[3-(Benzoxazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide (82)
Figure US06573264-20030603-C00085
Compound 82 was prepared in the manner of compound 39 by substituting 2-chloro-benzoxazole for 2-chloro-benzothiazole as in example 21. Mass Spectrum (MH+)=438.4.
EXAMPLE 23 Mitochondrial Assays
Rat heart mitochondria were isolated by the method of Nedergard and Cannon (Methods in Enzymol. 55, 3, 1979).
Palmitoyl CoA oxidation—The Palmityl CoA oxidation was carried out in a total volume of 100 micro liters containing the following agents: 110 mM KCl, 33 mM Tris buffer at pH 8, 2 mM KPi, 2 mM MgCl2, 0.1 mM EDTA, 14.7 microM defatted BSA, 0.5 mM malic acid, 13 mM carnitine, 1 mM ADP, 52 micrograms of mitochondrial protein, and 16 microM 1-C14 palmitoyl CoA (Sp. Activity 60 mCi/mmole; 20 microCi/ml, using 5 microliters per assay). The compounds of this invention were added in a DMSO solution at the following concentrations: 100 microM, and 50 microM. In each assay, a DMSO control was used. After 15 min at 30° C., the enzymatic reaction was centrifuged (20,000 g for 1 min), and 70 microliters of the supernatant was added to an activated reverse phase silicic acid column (approximately 0.5 ml of silicic acid). The column was eluted with 2 ml of water, and 0.5 ml of the eluent was used for scintillation counting to determine the amount of C14 trapped as C14 bicarbonate ion.
TABLE 1
Inhibition of mitochondrial fatty acid oxidation using palmitoyl CoA
as substrate - percent of inhibition at two concentrations and IC50.
Compound # 100 μm (%) 50 μm (%) IC50 (μm)
7 — 77 —
39 27 — —
43 21 — —
45 87 — ˜20
46 61 — ˜125
47 70 — ˜125
49 3 — —
52 95 — ˜1
54 81 — ˜8
60 — 61 —
62 — 62 —
64 41 — —
68 — 68 —
70 12 — —
72 8 — —
74 12 — —
76 26 — —
78 42 — —
80 22 — —
82 22 — —
EXAMPLE 25
Metabolic Stability: As a measure of metabolic stability the compounds of this invention were incubated with human liver S-9 microsomal fractions. After, 30 minutes at 37 C, the amount of parent drug remaining was determined using LC-mass spec. The response factors for each compound was determined by establishing a standard curve and using an internal standard during the analysis of the samples. An average of five experiments for percentage of ranolazine remaining at the 30 minute time point is 57%. The compounds of this invention were assayed as described in the protocol below and the percentage of parent remaining was divided by the average % of ranolazine remaining (57%) affording a metabolic stability factor. A compound with a stability number greater than 1.2 has a better stability than ranolazine in the liver S-9 assay. A compound with a stability number between 1.2 and 0.8 has an equivalent stability in the liver S-9 assay. A compound with a stability number less than 0.8 is less stable than ranolazine in the liver S-9 assay.
The purpose of this experiment is to compare the percentages remaining for compounds of this invention with the percentage remaining for ranolazine after 30 minutes of incubation with human liver S9 fractions.
Reagents:
The following reagents were used; Potassium phosphate, 0.5M pH 7.4 (incubation buffer), kept at room temperature; 0.05M MgCl2 kept at 4° C.; β-Nicotinamide adenine dinucleotide phosphate, tetrasodium salt, reduced form (NADPH), 0.02M solution in water (˜16.6 mg/mL) from Sigma Lot # 79H7044 prepared on day of use. 1 mM of ranolazine or Compounds 43, 45, 47, 52, 70, 74, 76, 78, and 80 in ACN further diluted to obtain 100 μM in 10% ACN; Human S9 stock: 20 mg/mL from Gentest.
Procedure:
Incubation mixtures were prepared as follows:
TABLE 2
Volume per 0.25 mL of Final
Component Incubation Mixture concentration
10 μM CVT 25 μL 10 μM
compounds
MgCl2 25 μL 0.005 M
NADPH 25 μL 0.002 M
S9 25 μL 2 mg/mL
Incubation Buffer 25 μL 0.05 M
Water 125 μL  —
*1% organic solvent (acetonitrile) was used in incubation mixture. Generally, 30 incubates were prepared at a time by pre-mixing 0.75 mL of MgCl2, 0.75 mL of incubation buffer, 0.75 mL of NADPH, 3.75 mL of water. Then pipette 200 μL/incubate, add 25 μL of compound being tested, mix, and initiate reaction by addition of S-9.
Combine all components with incubation buffer and re-pipette 200 μL/tube+25 μL of the compound being tested along with 25 μL of S-9.
After 5 min of pre-incubation at 37° C., at 0 and 30 min after starting the reaction, a 50 μl aliquot of the incubation mixture was removed and added to 100 μL of 9:1 acetonitrile: methanol containing the internal standard.
The mixture was centrifuged and a 100 μL aliquot of the supernatant was diluted in 1 mL of solvent C (0.1% Formic Acid in water). Then samples were analyzed for change between the ratio of compound to internal standard at time zero and 30 minutes by LC/MS (injected 10 μL).
Analytical and Data Calculations:
Samples were analyzed for the starting compounds and potential metabolite/s by LC/MS using an internal standard and an ODS-C18 column with a flow rate of 0.25 ml/min. Following the above procedure resulted in the following relative stability factors as compared to ranolize for the compounds of this invention as illustrated in Table 3.
TABLE 3
Compound # Liver S9 Stability Factor
43 0.6
45 0.8
46 1.1
47 1.5
52 0.5
70 0.1
74 1.0
76 0.8
78 0.6
80 0.5

Claims (41)

We claim:
1. A substituted piperazine compound having the following formula:
Figure US06573264-20030603-C00086
wherein m=1, 2, or 3;
q=NH, O, or S;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20 and C1-15 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen and C1-4 straight or branched alkyl, or wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl;
R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, quinoxalinyl, pyridinyl, quinolinyl, isoquinolinyl, and indolyl, wherein each group is optionally substituted with from 1 to 3 substituents selected from the group consisting of CON(R20)2, C1-15 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent selected from the group consisting of CF3; and
R20 is hydrogen.
2. The compound of claim 1 wherein q=NH or O;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20 and C1-8 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen and C1-4 straight or branched alkyl, or wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl;
R17 is selected from the group consisting of benzoxazolyl, benzothiazoly, quinoxalinyl, pyridinyl, quinolinyl, isoquinolinyl, and indolyl, wherein each group is optionally substituted with from 1 to 3 substituents selected from the group consisting of CON(R20)2, C1-15 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent selected from the group consisting of CF3; and
R20 is hydrogen.
3. The compound of claim 1 wherein R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20 and C1-5 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen and C1-4 straight or branched alkyl, or wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl;
R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, quinoxalinyl, pyridinyl, quinolinyl, isoquinolinyl, and indolyl, wherein each group is optionally substituted with from 1 to 2 substituents selected from the group consisting of CON(R20)2, C1-8 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent selected from the group consisting of CF3; and
R20 is hydrogen.
4. The compound of claim 1 wherein R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20 and C1-3 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen and C1-2 alkyl or wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl;
R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, quinoxalinyl, pyridinyl, quinolinyl, isoquinolinyl, and indolyl, wherein each group is optionally substituted with from 1 to 2 substituents selected from the group consisting of CON(R20)2, C1-5 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent selected from the group consisting of CF3; and
R20 is hydrogen.
5. The compound of claim 1 wherein m=1;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20 and C1-3 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen and methyl, or wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl;
R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, quinoxalinyl, pyridinyl, quinolinyl, isoquinolinyl, and indolyl, wherein each group is optionally substituted with from 1 to 2 substituents selected from the group consisting of CON(R20)2, C1-3 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of CF3; and
R20 is hydrogen.
6. The compound of claim 1 wherein R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, and indolyl, wherein each group is optionally substituted with from 1 to 3 substituent selected from the group consisting of CON(R20)2, C1-15 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of CF3.
7. The compound of claim 6 wherein q=NH, O;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20 and C1-8 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen and C1-4 straight or branched alkyl or wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl;
R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, and indolyl, wherein each group is optionally substituted with 1-3 substituents selected from the following CON(R20)2, C1-15 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent selected from the group consisting of CF3; and
R20 is hydrogen.
8. The compound of claim 6 wherein q=NH or O;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20 and C1-5 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen and C1-3 straight or branched alkyl, or wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl;
R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, and indolyl, wherein each group is optionally substituted with from 1 to 2 substituents selected from the group consisting of CON(R20)2, C1-8 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of CF3; and
R20 is hydrogen.
9. The compound of claim 6 wherein q=NH or O;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20 and C1-3 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen and C1-3 straight or branched alkyl, or wherein R9 and R10 may together form a carbonyl;
R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, and indolyl, wherein each group is optionally substituted with from 1 to 2 substituents selected from the group consisting of CON(R20)2, C1-4 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent selected from the group consisting of CF3; and
R20 is hydrogen.
10. A substituted piperazine compound having the following formula:
Figure US06573264-20030603-C00087
wherein q=NH or O;
m=1, 2 or 3;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20, and C1-3 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen, and C1-2 alkyl, or wherein R9 and R10 may together form a carbonyl;
R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, and indolyl, wherein each group is optionally substituted with from 1 to 2 substituents selected from the group consisting of CON(R20)2, C1-3 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent selected from the group consisting of CF3; and
R20 is hydrogen.
11. The compound of claim 10 wherein q=O; and
R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, and indolyl, wherein each group is optionally substituted with from 1 to 2 substituents selected from the group consisting of CON(R20)2, C1-3 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent selected from the group consisting of CF3.
12. A substituted piperazine compound having the following formula:
Figure US06573264-20030603-C00088
wherein q=O:
m=1, 2 or 3;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20 and C1-2 alkyl;
R6, R7 and R8 are each hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen and C1-2 alkyl, or wherein R9 and R10 may together form a carbonyl;
R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, and indolyl, wherein each group is optionally substituted with 1 substituent selected from the group consisting of CON(R20)2, C1-3 straight or branched alkyl, and aryl, wherein the aryl substituents are optionally substituted with 1 substituent selected from the group consisting of CF3; and
R20 is hydrogen.
13. The compound of claim 12 wherein R17 is a benzothiazolyl group that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, CON(R20)2, C1-3 straight or branched alkyl, and aryl, wherein the aryl substituents are optionally substituted with 1 a substituent selected from the group consisting of CF3.
14. The compound of claim 12 wherein R17 is a benzothiazolyl group that is optionally substituted at the 2-position with 1 substituent selected from the group consisting of hydrogen, methyl and phenyl.
15. The compound of claim 12 wherein R17 is a benzothiazol-5-yl group that is optionally substituted with 1 substituent selected from the group consisting of CON(R20)2, C1-3 straight or branched alkyl and aryl, wherein the aryl substituents are optionally substituted with 1 substituent selected from the group consisting of CF3,
R20 is hydrogen.
16. A compound of claim 12 wherein R17 is a benzothiazol-5-yl group that is optionally substituted at the 2-position with 1 substituent selected from the group consisting of hydrogen, methyl and phenyl; and
R20 is hydrogen.
17. A compound of claim 12 wherein q=O;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20 and methyl;
R6, R7 and R8 are each hydrogen;
R11 and R13 are each selected from the group consisting of hydrogen and methyl;
R9, R10, R12, R13, R14 and R16 are each hydrogen or R9 and R10 may together form a carbonyl;
R17 is that is substituted at the 2-position with methyl; and
R20 is hydrogen.
18. A compound of claim 12 wherein q=O;
R1, R2, R3, R4 and R5 are each independently selected tom the group consisting of hydrogen, OR20 and methyl;
R6, R7 and R8 are each hydrogen;
R11 and R13 are each selected from the group consisting of hydrogen and methyl;
R9, R10, R12, R14, R15 and R16 are each hydrogen or R9 and R10 may together form a carbonyl;
R17 is a benzothiazol-5-yl group that is substituted at the 2-position with phenyl; and
R20 is hydrogen.
19. A compound of claim 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 wherein R17 is a benzothiazol-5-yl group that is substituted at the 2-position with methyl.
20. A compound of claim 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15, or 16 wherein R17 is a benzothiazol-5-yl group that is substituted at the 2-position with phenyl.
21. The compound of claim 1 wherein R17 is selected from the group consisting of quinoxalinyl, quinolinyl and isoquinolinyl, wherein each group is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen and C1-15 straight or branched alkyl.
22. The compound of claim 21 wherein q=O;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen and C1-8 straight or branched alkyl;
R6, R7 and R are each independently hydrogen; and
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently hydrogen.
23. A substituted piperazine compound having the following formula;
Figure US06573264-20030603-C00089
wherein q=O;
m=1, 2, or 3
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen and C1-5 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently hydrogen; and
R17 is selected from the group consisting of quinoxalinyl, quinolinyl and isoquinolinyl, wherein each group is optionally substituted with from 1 to 2 substituents selected from the group consisting of and C1-8 straight or branched alkyl.
24. The compound of claim 23 wherein q=O;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, OR20 and methyl;
R6, R7 and R8 are each hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently hydrogen; and
R17 is selected from the group consisting of quinoxalinyl, quinolinyl and isoquinolinyl, wherein each group is optionally substituted with methyl.
25. The compound of claim 24 wherein q=O;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen and methyl;
R6, R7 and R8 are each hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each hydrogen; and
R17 is selected from the group consisting of quinoxalinyl, quinolinyl and isoquinolinyl, wherein each group is optionally substituted with methyl.
26. The compound of claim 1 wherein R17 is a pyridinyl group.
27. The compound of claim 26 wherein q=O;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen and C1-8 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently hydrogen,
R17 is a pyridinyl group.
28. A substituted piperazine compound having the following formula:
Figure US06573264-20030603-C00090
wherein q=O;
m=1, 2 or 3;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen and C1-5 straight or branched alkyl;
R6, R7 and R8 are each independently hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently hydrogen; and
R17 is a pyridinyl group.
29. The compound of claim 28 wherein q=O;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen and methyl;
R6, R7 and R8 are each hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently hydrogen; and
R17 is a pyridinyl group.
30. The compound of claim 10 wherein q=NH; and
R17 is selected from the group consisting of benzoxazolyl, benzothiazolyl, and indolyl.
31. A substituted piperazine compound having the following formula:
Figure US06573264-20030603-C00091
wherein q=NH;
m=1, 2, or 3;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen and C1-2 alkyl;
R6, R7 and R8 are each hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently hydrogen; and
R17 is selected from the group consisting of benzothiazolyl and benzoxazolyl, wherein each group is optionally substituted with 1 substituent selected from the group consisting of C1-3 straight or branched alkyl.
32. A substituted piperazine compound having the following formula:
Figure US06573264-20030603-C00092
wherein q=NH;
m=1, 2, or 3;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen and methyl;
R6, R7 and R8 are each hydrogen;
R9, R10, R11, R12, R13, R14, R15 and R16 are each hydrogen; and
R17 is selected from the group consisting of benzothiazolyl and benzoxazolyl, wherein each group is optionally substituted with methyl.
33. A compound selected from the group consisting of
N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide,
2-{4-[3-(benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethylphenyl)acetamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide,
4-(3-{4-[(2,6-dimethylphenylcarbamoyl)-methyl]-piperazin-1-yl}-2-hydroxy-propoxy)-1H-indole-2-carboxylic acid amide;2-{4-[3-(benzothiazol-6-yloxy)2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethyl-phenyl)-acetamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-6-yloxy)-propyl]-piperazin-1-yl}aceamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-3,5-dimethyl-piperazine-1-yl}acetamide,
2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-N-(4-hydroxy-phenyl)acetamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide,
N-(2,6-dimethylphenyl)2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-7-yloxy)-propyl]-piperazin-1-ylacetamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-2-oxo-piperazin-1-yl}acetamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide,
N-(2,6-dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(4-trifluoromethyl-phenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinoxalin-2-yloxy)-propyl]-piperazin-1-yl}acetamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-pyridin-3-yloxy)-propyl]-piperazin-1-yl}acetamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-4-yloxy)-propyl]-piperazin-1-yl}acetamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propyl]-piperazin-1-yl}acetamide,
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propyl]-piperazin-1-yl}acetamide,
N(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-quinolin-7-yloxy)-propyl]-piperazin-1-yl}acetamide,
2-{4-[3-(benzothiazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, and
2-{4-[3-(benzoxazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide.
34. A method of treatment comprising administering a therapeutically effective amount of a compound of claim 1 to a mammal in need of a treatment selected from the group consisting of protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles subsequent to muscle or systemic diseases, treating shock conditions, preserving donor tissue and organs used in transplants, and treating cardiovascular diseases.
35. The method of claim 34 wherein the cardiovascular disease is selected from the group consisting of atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, exercise induced angina, congestive heart disease, and myocardial infarction.
36. The method of claim 34 or 35 wherein the therapeutically effective amount ranges from about 0.01 to about 100 mg/kg weight of the mammal.
37. The method of claim 34 or 35 wherein the mammal is a human.
38. A pharmaceutical composition comprising a compound of claim 1 and one or more pharmaceutical excipients.
39. The pharmaceutical composition of claim 38 wherein the pharmaceutical composition is in the form of a solution.
40. The pharmaceutical composition of claim 38 wherein the pharmaceutical composition is in a form selected from the group consisting of a tablet and a capsule.
41. A method of preserving donor tissue and organs used in transplants, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of claim 1.
US09/694,155 2000-10-23 2000-10-23 Heteroaryl alkyl piperazine derivatives Expired - Fee Related US6573264B1 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
US09/694,155 US6573264B1 (en) 2000-10-23 2000-10-23 Heteroaryl alkyl piperazine derivatives
CA002426535A CA2426535A1 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
EP01271075A EP1339701B1 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
PL36200401A PL362004A1 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
US10/398,636 US20040029889A1 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
PCT/US2001/051032 WO2002064576A1 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
DE60126643T DE60126643T2 (en) 2000-10-23 2001-10-19 HETEROARYL ALKYLPIPERAZINE DERIVATIVES AS FATTY ACID DEFICIENCY INGREDIENTS
NZ525259A NZ525259A (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
MXPA03003531A MXPA03003531A (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors.
SI200130708T SI1339701T1 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
IL15529401A IL155294A0 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
CNB018177700A CN1303074C (en) 2000-10-23 2001-10-19 Heteroarylalkylpiperazine derivatives as fatty acid oxidation inhibitors
AU2002255466A AU2002255466B2 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
KR10-2003-7005645A KR20030044029A (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
RU2003115351/04A RU2243970C1 (en) 2000-10-23 2001-10-19 Derivatives of heteroarylalkylpiperazine and pharmaceutical composition based on thereof
AT01271075T ATE353882T1 (en) 2000-10-23 2001-10-19 HETEROARYLALKYL PIPERAZINE DERIVATIVES AS PARTIAL INHIBITORS OF FATTY ACID OXIDATION
PT01271075T PT1339701E (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
HU0303552A HUP0303552A3 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors and pharmaceutical compositions containing them
JP2002564509A JP4138489B2 (en) 2000-10-23 2001-10-19 Heteroarylalkylpiperazine derivatives as fatty acid antioxidants
ES01271075T ES2279790T3 (en) 2000-10-23 2001-10-19 HETEROARILALQUILPIPERAZINA DERIVATIVES AS INHIBITORS OF OXIDATION OF FATTY ACIDS.
HK04101193.9A HK1058364B (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
TW090126173A TWI286135B (en) 2000-10-23 2001-10-23 Heteroaryl alkyl piperazine derivatives
ARP010104957A AR034173A1 (en) 2000-10-23 2001-10-23 A COMPOSITE OF REPLACED PIPERAZINE, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE PREPARATION OF MEDICINES
US10/313,818 US6849632B2 (en) 2000-10-23 2002-12-05 Heteroaryl alkyl piperazine derivatives
IL155294A IL155294A (en) 2000-10-23 2003-04-08 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
ZA200302990A ZA200302990B (en) 2000-10-23 2003-04-16 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors.
NO20031784A NO20031784L (en) 2000-10-23 2003-04-22 Heteroarylalkylpiperazine derivatives as fatty acid oxidation inhibitors
NO20031797A NO325220B1 (en) 2000-10-23 2003-04-22 Substituted piperazine compound, its use as well as pharmaceutical composition containing the compound
US10/813,743 US20040192702A1 (en) 2000-10-23 2004-03-31 Heteroaryl alkyl piperazine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/694,155 US6573264B1 (en) 2000-10-23 2000-10-23 Heteroaryl alkyl piperazine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/313,818 Continuation-In-Part US6849632B2 (en) 2000-10-23 2002-12-05 Heteroaryl alkyl piperazine derivatives

Publications (1)

Publication Number Publication Date
US6573264B1 true US6573264B1 (en) 2003-06-03

Family

ID=24787627

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/694,155 Expired - Fee Related US6573264B1 (en) 2000-10-23 2000-10-23 Heteroaryl alkyl piperazine derivatives
US10/398,636 Abandoned US20040029889A1 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
US10/313,818 Expired - Lifetime US6849632B2 (en) 2000-10-23 2002-12-05 Heteroaryl alkyl piperazine derivatives
US10/813,743 Abandoned US20040192702A1 (en) 2000-10-23 2004-03-31 Heteroaryl alkyl piperazine derivatives

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/398,636 Abandoned US20040029889A1 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
US10/313,818 Expired - Lifetime US6849632B2 (en) 2000-10-23 2002-12-05 Heteroaryl alkyl piperazine derivatives
US10/813,743 Abandoned US20040192702A1 (en) 2000-10-23 2004-03-31 Heteroaryl alkyl piperazine derivatives

Country Status (23)

Country Link
US (4) US6573264B1 (en)
EP (1) EP1339701B1 (en)
JP (1) JP4138489B2 (en)
KR (1) KR20030044029A (en)
CN (1) CN1303074C (en)
AR (1) AR034173A1 (en)
AT (1) ATE353882T1 (en)
AU (1) AU2002255466B2 (en)
CA (1) CA2426535A1 (en)
DE (1) DE60126643T2 (en)
ES (1) ES2279790T3 (en)
HU (1) HUP0303552A3 (en)
IL (2) IL155294A0 (en)
MX (1) MXPA03003531A (en)
NO (2) NO20031784L (en)
NZ (1) NZ525259A (en)
PL (1) PL362004A1 (en)
PT (1) PT1339701E (en)
RU (1) RU2243970C1 (en)
SI (1) SI1339701T1 (en)
TW (1) TWI286135B (en)
WO (1) WO2002064576A1 (en)
ZA (1) ZA200302990B (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176447A1 (en) * 2001-07-19 2003-09-18 Prabha Ibrahim Substituted heterocyclic compounds
US20030181352A1 (en) * 2001-07-19 2003-09-25 Prabha Ibrahim Substituted heterocyclic compounds
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20040152890A1 (en) * 2002-12-05 2004-08-05 Elfatih Elzein Substituted heterocyclic compounds
US20040176356A1 (en) * 2003-01-03 2004-09-09 Venkata Palle Substituted heterocyclic compounds
US20040176383A1 (en) * 2002-07-18 2004-09-09 Prabha Ibrahim Substituted heterocyclic compounds
US20040186109A1 (en) * 2003-01-17 2004-09-23 Robert Jiang Substituted heterocyclic compounds
US20040192702A1 (en) * 2000-10-23 2004-09-30 Jeff Zablocki Heteroaryl alkyl piperazine derivatives
US20050049254A1 (en) * 2003-06-23 2005-03-03 Jeff Zablocki Substituted heterocyclic compounds
US20050159416A1 (en) * 2003-01-14 2005-07-21 Morgan Bradley P. Compounds, compositions and methods
US20060052605A1 (en) * 2004-09-08 2006-03-09 Jeff Zablocki Substituted heterocyclic compounds
US20060074105A1 (en) * 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
US7115610B2 (en) 2003-12-18 2006-10-03 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US20070066626A1 (en) * 2005-08-04 2007-03-22 Morgan Bradley P Compounds, compositions and methods
US20070161617A1 (en) * 2005-12-15 2007-07-12 Morgan Bradley P Certain chemical entities, compositions and methods
US20070197497A1 (en) * 2005-12-19 2007-08-23 Morgan Bradley P Compounds, compositions and methods
US20070197507A1 (en) * 2005-12-16 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
US20070197504A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US20090099198A1 (en) * 2004-06-17 2009-04-16 Cytokinetics, Inc. Compounds, Compositions and Methods
US20090247544A1 (en) * 2005-12-15 2009-10-01 Cytokinetics, Inc. Certain Chemical Entities, Compositions and Methods
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
CN114805112A (en) * 2022-05-31 2022-07-29 常州大学 PDE2 inhibitor amide derivative and preparation method thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
EP1806346B1 (en) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
US7163944B2 (en) * 2004-01-26 2007-01-16 Kowa Co., Ltd. Cyclic diamine compound and pharmaceutical containing the same
JP2008533044A (en) * 2005-03-11 2008-08-21 ホン コン ナイトリック オキサイド リミテッド Combination therapy for endothelial dysfunction, angina and diabetes
TW200745025A (en) * 2005-12-29 2007-12-16 Schering Ag Amide inhibitors of leukotriene A4 hydrolase
WO2010056527A2 (en) * 2008-10-30 2010-05-20 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
US8759382B2 (en) 2010-09-29 2014-06-24 Teva Pharmaceutical Industries Ltd. Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use
ES2898965T3 (en) 2014-08-29 2022-03-09 Chdi Foundation Inc Huntingtin protein imaging probes
US10556013B2 (en) 2017-06-20 2020-02-11 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
WO2020081361A1 (en) 2018-10-17 2020-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
RU2751878C2 (en) * 2018-12-06 2021-07-19 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" 1-(methoxybenzyl)-4-[2-((methoxybenzyl)amino)ethyl]piperazines, which have antiarrhythmic activity
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
EP0407780A2 (en) 1989-06-23 1991-01-16 Syntex Pharmaceuticals Ltd. Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult
US5472707A (en) * 1993-05-13 1995-12-05 Syntex (U.S.A.) Inc. High dose ranolazine formulations
WO2001062749A1 (en) 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2574585B2 (en) * 1989-11-22 1997-01-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Drugs to prevent or limit reperfusion injury
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
EP0407780A2 (en) 1989-06-23 1991-01-16 Syntex Pharmaceuticals Ltd. Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult
US5506229A (en) * 1989-06-23 1996-04-09 Syntex Pharmaceuticals, Ltd. Methods of treatment using ranolazine and related piperazine derivatives
US5472707A (en) * 1993-05-13 1995-12-05 Syntex (U.S.A.) Inc. High dose ranolazine formulations
WO2001062749A1 (en) 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
McCormick, et al. "Ranolazine: A Novel Metabolic Modulator for the Treatment of Angina", Gen Pharmac., vol. 30, No. 5, pp. 639-645, (1998).

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192702A1 (en) * 2000-10-23 2004-09-30 Jeff Zablocki Heteroaryl alkyl piperazine derivatives
US6849632B2 (en) * 2000-10-23 2005-02-01 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US6930111B2 (en) 2001-07-19 2005-08-16 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US20030181352A1 (en) * 2001-07-19 2003-09-25 Prabha Ibrahim Substituted heterocyclic compounds
US20030176447A1 (en) * 2001-07-19 2003-09-18 Prabha Ibrahim Substituted heterocyclic compounds
US7001909B2 (en) 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20100004255A1 (en) * 2002-04-04 2010-01-07 Luiz Belardinelli Method of treating arrhythmias
US7056924B2 (en) 2002-07-18 2006-06-06 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US20040176383A1 (en) * 2002-07-18 2004-09-09 Prabha Ibrahim Substituted heterocyclic compounds
US7125876B2 (en) 2002-12-05 2006-10-24 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US20040152890A1 (en) * 2002-12-05 2004-08-05 Elfatih Elzein Substituted heterocyclic compounds
US7407960B2 (en) * 2002-12-05 2008-08-05 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US20070004751A1 (en) * 2002-12-05 2007-01-04 Elfatih Elzein Substituted heterocyclic compounds
US20040176356A1 (en) * 2003-01-03 2004-09-09 Venkata Palle Substituted heterocyclic compounds
US7205303B2 (en) 2003-01-03 2007-04-17 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US20050159416A1 (en) * 2003-01-14 2005-07-21 Morgan Bradley P. Compounds, compositions and methods
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
US20060241110A1 (en) * 2003-01-14 2006-10-26 Morgan Bradley P Compounds, compositions, and methods
US20090176307A1 (en) * 2003-01-14 2009-07-09 Cytokinetics, Inc. Compounds, Compositions and Methods
US7491826B2 (en) 2003-01-14 2009-02-17 Cytokinetics, Inc. Compounds, compositions and methods
US7026321B2 (en) 2003-01-17 2006-04-11 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US20040186109A1 (en) * 2003-01-17 2004-09-23 Robert Jiang Substituted heterocyclic compounds
US7208496B2 (en) 2003-06-23 2007-04-24 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US20050049254A1 (en) * 2003-06-23 2005-03-03 Jeff Zablocki Substituted heterocyclic compounds
US7115610B2 (en) 2003-12-18 2006-10-03 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US8110595B2 (en) 2004-06-17 2012-02-07 Cytokinetics, Inc. Ureas and their use in the treatment of heart failure
US9150564B2 (en) 2004-06-17 2015-10-06 Cytokinetics, Inc. Compounds, compositions and methods
US12264133B2 (en) 2004-06-17 2025-04-01 Cytokinetics, Incorporated Compounds, compositions and methods
US10975034B2 (en) 2004-06-17 2021-04-13 Cytokinetics, Inc. Compounds, compositions and methods
US8513257B2 (en) 2004-06-17 2013-08-20 Cytokinetics, Incorporated Ureas and their use in the treatment of heart failure
US10385023B2 (en) 2004-06-17 2019-08-20 Cytokinetics, Inc. Compounds, compositions and methods
US10035770B2 (en) 2004-06-17 2018-07-31 Cytokinetics, Incorporated Compounds, compositions and methods
US8871769B2 (en) 2004-06-17 2014-10-28 Cytokinetics, Inc. Ureas and their use in the treatment of heart failure
US20090099198A1 (en) * 2004-06-17 2009-04-16 Cytokinetics, Inc. Compounds, Compositions and Methods
US8101617B2 (en) 2004-06-17 2012-01-24 Amgen, Inc. Disubstituted ureas and uses thereof in treating heart failure
US9643925B2 (en) 2004-06-17 2017-05-09 Cytokinetics, Incorporated Compounds, compositions and methods
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US7271169B2 (en) 2004-09-08 2007-09-18 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US20060052605A1 (en) * 2004-09-08 2006-03-09 Jeff Zablocki Substituted heterocyclic compounds
US20060074105A1 (en) * 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US20070066626A1 (en) * 2005-08-04 2007-03-22 Morgan Bradley P Compounds, compositions and methods
US8871768B2 (en) 2005-12-15 2014-10-28 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US20100029680A1 (en) * 2005-12-15 2010-02-04 Cytokinetics, Inc. Certain Chemical Entities, Compositions and Methods
US20070197504A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US8445495B2 (en) 2005-12-15 2013-05-21 Cytokinetics, Inc. Certain Chemical entities, compositions and methods
US20070161617A1 (en) * 2005-12-15 2007-07-12 Morgan Bradley P Certain chemical entities, compositions and methods
US20090247544A1 (en) * 2005-12-15 2009-10-01 Cytokinetics, Inc. Certain Chemical Entities, Compositions and Methods
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
US20070197507A1 (en) * 2005-12-16 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
US8653081B2 (en) 2005-12-16 2014-02-18 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US20100210634A1 (en) * 2005-12-16 2010-08-19 Cytokinetics, Inc. Certain Chemical Entities, Compositions and Methods
US8410108B2 (en) 2005-12-16 2013-04-02 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US20070197497A1 (en) * 2005-12-19 2007-08-23 Morgan Bradley P Compounds, compositions and methods
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
CN114805112A (en) * 2022-05-31 2022-07-29 常州大学 PDE2 inhibitor amide derivative and preparation method thereof

Also Published As

Publication number Publication date
DE60126643D1 (en) 2007-03-29
AU2002255466B2 (en) 2004-07-15
IL155294A0 (en) 2003-11-23
NO20031797D0 (en) 2003-04-22
EP1339701B1 (en) 2007-02-14
PT1339701E (en) 2007-03-30
RU2243970C1 (en) 2005-01-10
CA2426535A1 (en) 2002-08-22
KR20030044029A (en) 2003-06-02
NZ525259A (en) 2004-10-29
AR034173A1 (en) 2004-02-04
SI1339701T1 (en) 2007-06-30
MXPA03003531A (en) 2005-01-25
EP1339701A1 (en) 2003-09-03
US20030216409A1 (en) 2003-11-20
TWI286135B (en) 2007-09-01
US20040192702A1 (en) 2004-09-30
US6849632B2 (en) 2005-02-01
NO20031797L (en) 2003-06-19
HK1058364A1 (en) 2004-05-14
JP2004518725A (en) 2004-06-24
HUP0303552A3 (en) 2004-06-28
DE60126643T2 (en) 2007-10-31
NO20031784D0 (en) 2003-04-22
NO20031784L (en) 2003-04-23
PL362004A1 (en) 2004-10-18
ATE353882T1 (en) 2007-03-15
JP4138489B2 (en) 2008-08-27
IL155294A (en) 2009-02-11
ZA200302990B (en) 2004-04-22
US20040029889A1 (en) 2004-02-12
ES2279790T3 (en) 2007-09-01
NO325220B1 (en) 2008-02-25
WO2002064576A1 (en) 2002-08-22
HUP0303552A2 (en) 2004-04-28
CN1628107A (en) 2005-06-15
CN1303074C (en) 2007-03-07

Similar Documents

Publication Publication Date Title
US6573264B1 (en) Heteroaryl alkyl piperazine derivatives
AU2002255466A1 (en) Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
US6552023B2 (en) Aralkyl substituted piperazine compounds
US6451798B2 (en) Substituted alkyl piperazine derivatives
US6677336B2 (en) Substituted piperazine compounds
JP2007211009A (en) Substituted piperazine compound
US6677343B2 (en) Substituted piperazine compounds
JPH10139780A (en) New heterocyclic aminomethyl compound, production thereof and medicinal composition containing the same
US6638970B2 (en) Substituted alkylene diamine compounds
AU2001238623A1 (en) Substituted piperazine compounds
HK1058364B (en) Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
JPS6293272A (en) Piperazine derivatives and their production method

Legal Events

Date Code Title Description
AS Assignment

Owner name: CV THERAPEUTICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZABLOCKI, JEFF A.;IBRAHIM, PRABHA N.;SHENK, KEVIN;AND OTHERS;REEL/FRAME:011330/0528;SIGNING DATES FROM 20001013 TO 20001020

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20150603